<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Long‐acting inhaled bronchodilators for cystic fibrosis - Smith, S - 2017 | Cochrane Library</title> <meta content="Long‐acting inhaled bronchodilators for cystic fibrosis - Smith, S - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012102.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Long‐acting inhaled bronchodilators for cystic fibrosis - Smith, S - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012102.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012102.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Long‐acting inhaled bronchodilators for cystic fibrosis" name="citation_title"/> <meta content="Sherie Smith" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Sherie.Smith@nottingham.ac.uk" name="citation_author_email"/> <meta content="Christopher T Edwards" name="citation_author"/> <meta content="A Floor, Clarendon Wing, Leeds Children's Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD012102.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/12/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012102.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012102.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012102.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenergic beta-2 Receptor Agonists [administration &amp; dosage, *therapeutic use]; Bronchodilator Agents [administration &amp; dosage, *therapeutic use]; Cystic Fibrosis [*drug therapy]; Disease Progression; Forced Expiratory Volume [drug effects]; Muscarinic Antagonists [administration &amp; dosage, *therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Tiotropium Bromide [administration &amp; dosage, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012102.pub2&amp;doi=10.1002/14651858.CD012102.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012102\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012102\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012102.pub2",title:"Long\\u2010acting inhaled bronchodilators for cystic fibrosis",firstPublishedDate:"Dec 18, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012102.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012102.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012102.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012102.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012102.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012102.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012102.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012102.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012102.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012102.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5170 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012102.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-sec-0115"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/appendices#CD012102-sec-0120"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/table_n/CD012102StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/table_n/CD012102StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Long‐acting inhaled bronchodilators for cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/information#CD012102-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Sherie Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012102.pub2/information#CD012102-cr-0005">Christopher T Edwards</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/information/en#CD012102-sec-0128">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 December 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012102.pub2">https://doi.org/10.1002/14651858.CD012102.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012102-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012102-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012102-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012102-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012102-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012102-abs-0001" lang="en"> <section id="CD012102-sec-0001"> <h3 class="title" id="CD012102-sec-0001">Background</h3> <p>Cystic fibrosis is a life‐limiting inherited condition which affects one in 2500 newborns in the UK and 70,000 children and adults worldwide. The condition is multifaceted and affects many systems in the body. The respiratory system is particularly affected due to a build up of thickened secretions and a predisposition to infection. Inhaled bronchodilators are prescribed for 80% of people with cystic fibrosis in order to widen the airways and alleviate symptoms. Both short‐ and long‐acting inhaled bronchodilators are used to improve respiratory symptoms. Short‐acting inhaled bronchodilators take effect in minutes and typically last for four to eight hours (muscarinic antagonists). Long‐acting inhaled bronchodilators also take effect within minutes but typically last for around 12 hours and sometimes longer. This review is one of two which are replacing a previously published review of both long‐ and short‐acting inhaled bronchodilators. However, due to the lack of research in this area, we do not envisage undertaking any further updates of this long‐acting inhaled bronchodilators review. </p> </section> <section id="CD012102-sec-0002"> <h3 class="title" id="CD012102-sec-0002">Objectives</h3> <p>This review aims to evaluate long‐acting inhaled bronchodilators in children and adults with cystic fibrosis in terms of clinical outcomes and safety. If possible, we aimed to assess the optimal drug and dosage regimen. </p> </section> <section id="CD012102-sec-0003"> <h3 class="title" id="CD012102-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. </p> <p>Date of last search: 10 October 2017.</p> <p>We also carried out a separate search of Embase and the reference lists of included trials. We searched clinical trials registries for any ongoing trials and made contact with pharmaceutical companies for any further trials. </p> <p>Date of Embase search: 11 October 2017.</p> </section> <section id="CD012102-sec-0004"> <h3 class="title" id="CD012102-sec-0004">Selection criteria</h3> <p>Randomised or quasi‐randomised parallel trials comparing long‐acting inhaled bronchodilators (beta‐2 agonists and muscarinic antagonists) with placebo, no treatment or a different long‐acting inhaled bronchodilator in adults and children with cystic fibrosis. </p> </section> <section id="CD012102-sec-0005"> <h3 class="title" id="CD012102-sec-0005">Data collection and analysis</h3> <p>Both authors independently assessed trials for inclusion (based on title, abstract and full text). The authors independently assessed the included trials for quality and risk of bias and extracted data. Discrepancies were resolved by a third party. </p> </section> <section id="CD012102-sec-0006"> <h3 class="title" id="CD012102-sec-0006">Main results</h3> <p>The searches identified 195 unique references, of which 155 were excluded on title and abstract. We assessed the full texts of the remaining references, excluded 16 trials (28 references) and included four trials (12 references) in the review with 1082 participants. </p> <p>One trial (n = 16) measuring the effect of beta‐2 agonists reported an improvement in forced expiratory volume at one second (FEV<sub>1</sub>) after treatment (at one month), but the trial was small with an unclear risk of bias so we judged the evidence to be very low quality. The trial did not report on participant‐reported outcomes, quality of life or adverse events. </p> <p>Three trials (n = 1066) looked at the effects of the muscarinic antagonist tiotropium at doses of 2.5 µg and 5.0 µg in both the short term (up to 28 days) and the longer term (up to three months). Only one of the trials reported the change in FEV<sub>1</sub> (L) after 28 days treatment and showed no significant difference between groups; with 2.5 µg tiotropium, mean difference (MD) ‐0.02 (95% confidence interval (CI) ‐0.13 to 0.09), or 5.0 µg tiotropium, MD 0.00 (95% CI ‐0.10 to 0.10) (moderate‐quality evidence). All three trials of muscarinic antagonists provided data on adverse events which were found to differ little from placebo at doses of 2.5 µg, risk ratio (RR) 1.01 (95% CI 0.92 to 1.11) or 5.0 µg, RR 0.98 (95% CI 0.90 to 1.06). Very little participant‐reported outcome data or quality of life data were available for analysis. Two of the trials were at low risk of bias overall whilst the remaining trial was at an unclear risk overall. </p> </section> <section id="CD012102-sec-0007"> <h3 class="title" id="CD012102-sec-0007">Authors' conclusions</h3> <p>Neither long‐acting beta‐2 agonists nor long‐acting muscarinic antagonist bronchodilators demonstrate improvement in our primary outcome of FEV<sub>1</sub>. No difference was observed between intervention and placebo in terms of quality of life or adverse events. The quality of evidence for the use of beta‐2 agonists was very low. The use of a long‐acting inhaled bronchodilator may help to reduce the burden of treatment for people with cystic fibrosis as it is taken less often than a short‐acting inhaled bronchodilator, but future trials would benefit from looking at the effects on our primary outcomes (spirometric changes from baseline, quality of life and adverse effects) in the longer term. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012102-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012102-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012102-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012102-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012102-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012102-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012102-abs-0002" lang="en"> <h3>Long‐acting inhaled treatment to open up the airways in cystic fibrosis</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence for the benefit of long‐acting inhaled bronchodilators (treatment which opens up the airways often called "relievers") in people with cystic fibrosis. </p> <p><b>Background</b> </p> <p>Cystic fibrosis affects many systems in the body, in particular how well the lungs work. There is a build‐up of thickened, sticky mucus which makes breathing more difficult and makes people with cystic fibrosis more likely to get infections in their lungs. Short‐ and long‐acting bronchodilators are prescribed for most people with cystic fibrosis to widen the airways and improve symptoms. This review partly replaces an earlier review of both short‐acting and long‐acting inhaled bronchodilators. However, due to the lack of research in this area, we do not plan to update this review of long‐acting inhaled bronchodilators again. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 10 October 2017.</p> <p><b>Trial characteristics</b> </p> <p>We included four trials in our review, with a total of 1082 people whose ages ranged from five months to 70 years. The trials included in the review looked at the effects of two different types of long‐acting inhaled bronchodilator (beta‐2 agonists e.g. salmeterol, and muscarinic antagonists e.g. tiotropium). The trials lasted between 28 days and 12 weeks. </p> <p><b>Key results</b> </p> <p>The small trial of beta‐2 agonists compared to placebo (no active medication) reported some improvement in lung function (forced expiratory volume at one second (FEV<sub>1</sub>)) after treatment, but did not provide data we could analyse. They did not report on any side effects. </p> <p>Only one of the three trials comparing tiotropium to a placebo reported on FEV<sub>1</sub> (measured in litres) and found little difference between treatment and placebo. Two of these trials reported on quality of life, but there was not enough evidence to comment on whether this improved or not. Three trials noted side effects, some of which were seen after treatment with tiotropium, but these symptoms were also seen in the group of people who were given placebo. Future trials would improve our knowledge if they measure side effects and quality of life in a more meaningful way. </p> <p><b>Quality of the evidence</b> </p> <p>Only 16 people took part in the trial of the beta‐2 agonist which only lasted for 28 days, which makes the results less reliable. The trials of muscarinic antagonists included 1066 people and the trials appeared to be well run. We don't think any design factors will have influenced the results in a negative way. </p> <p>None of the trials ran for more than 12 weeks which makes it difficult to comment on the effects over a longer time period. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012102-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012102-sec-0115"></div> <h3 class="title" id="CD012102-sec-0116">Implications for practice</h3> <section id="CD012102-sec-0116"> <p>Since the publication of the previous Cochrane Review on bronchodilators for people with cystic fibrosis (CF) there has been no significant advance in the literature for evidence for long‐acting beta‐2 agonists. The evidence presented here is very low quality and does not add to our understanding of the effects on our specified outcomes. </p> <p>The trials of long‐acting muscarinic antagonists presented here are more robust than those of long‐acting beta‐2 agonists. The trials of muscarinic antagonists demonstrated no significant between tiotropium compared to placebo in our primary outcome of change from baseline in forced expiratory volume in one second (FEV<sub>1</sub>) (L), although there was a significant increase in an alternative measure of FEV<sub>1</sub> (FEV<sub>1</sub> area under the curve (AUC)<sub>0-4h</sub>). This measure was chosen by the trial authors as it gives a better measure of the effect over time. However, it is not a measure that is currently used in clinical practice (<a href="./references#CD012102-bbs2-0036" title="NICE. Cystic fibrosis: diagnosis and management draft for consultation. https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0736/documents May 04 2017.">NICE 2017</a>). </p> <p>We found moderate‐quality evidence that there was no significant effect on quality of life as measured by Cystic Fibrosis Quaity of Life ‐ Revised (CFQ‐R) and higher‐quality evidence that there were no significant differences in adverse events between tiotropium and placebo. </p> <p>Given the burden of treatment that people with CF already have, clinical benefit of a long‐acting bronchodilator should be proven to justify its continuing use. This could be clinically through reduction in symptoms or improvement in spirometry through reversibility testing. Without evidence of a clinical benefit, current practice regarding the use of long‐acting muscarinic antagonists in people with CF should not change. In line with our conclusions on the use of long‐acting beta‐2 agonists, individuals may benefit from using muscarinic antagonists, but there is not enough evidence to support their use in the whole CF population. </p> </section> <h3 class="title" id="CD012102-sec-0117">Implications for research</h3> <section id="CD012102-sec-0117"> <p>There is limited evidence that either long‐acting beta‐2 agonist or muscarinic antagonist bronchodilators are effective in improving measures of lung function and this is mainly in the short term. Four trials were excluded due to the cross‐over design being inappropriate for looking at the effects of long‐acting medication. If we want to assess the long‐term effects of long‐acting bronchodilators, larger trials of a more robust design (to reduce bias) are required. Parallel trials are much more appropriate for determining the effects of bronchodilators in a population where lung function is unstable and is generally progressive. </p> <p>The objectives of our review were primarily to look at the effect of long‐acting bronchodilators on FEV<sub>1</sub>, participant‐reported outcomes (e.g. quality of life) and adverse events. All the trials looked at the effect of treatment on measures of lung function, although the more rigorous trials looked only at FEV<sub>1</sub> AUC<sub>0-4h</sub> rather than change in FEV<sub>1</sub> from baseline (either as % predicted or in L). Future trials could improve the evidence base if there was a consistent use of the same outcome measures (particularly measures which are meaningful in the clinical area) over the same time‐scales. </p> <p>Only two trials assessed quality of life using CFQ‐R scores. These were also the only trials to report on pulmonary exacerbations; no trials looked at hospitalisation. This is likely to be due to the fact that they were medium‐term trials and not of sufficient duration to measure these outcomes. It is important that any future trials measure outcomes which are used in the clinical area and are meaningful to both clinicians and patients. Trials need to be of a sufficient duration to study the effects on outcomes which may be of equal importance to people with CF, such as improvements in quality of life and respiratory symptoms. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012102-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012102-sec-0008"></div> <div class="table" id="CD012102-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Beta‐2 agonists versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐2 agonists (salmeterol) compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> hospital inpatients </p> <p><b>Intervention:</b> long‐acting beta‐2 agonist (salmeterol) </p> <p><b>Comparison:</b> inhaled placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>salmeterol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub>: change from baseline </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Children who received salmeterol twice a day showed a significant increase in FEV<sub>1</sub> compared to children who received no treatment P &lt; 0.05. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This trial included only children. The unit of measurement was not specified and only a P value was presented. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant‐reported outcomes: quality of life (measured by CFQ‐R)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events after tiotropium 5.0 µg</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary exacerbations</p> <p>Follow‐up: N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other measures of lung function</p> <p>Follow‐up: N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEF<sub>25-75</sub> </b> : mid peak expiratory flow; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>FVC</b> : forced vital capacity; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded twice due to risk of bias ‐ this trial was at high risk of bias for blinding and at unclear risk of bias for four of the remaining five domains. The randomisation process and allocation concealment were unclear which was reflected in the risk of bias assessment. </p> <p>2. Downgraded once due to imprecision ‐ very small sample size from one trial.</p> <p>3. Downgraded once due to indirectness ‐ the trial only included children.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012102-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">LAMAs versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Inhaled tiotropium compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> inhaled tiotropium 2.5 µg to 5.0 µg </p> <p><b>Comparison:</b> inhaled placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Tiotropium</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub>: mean change from baseline (L) </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (L) in the placebo group ranged from ‐0.02 to zero. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (L) after tiotropium 2.5 µg was 0.02 L lower than placebo (0.13 lower to 0.09 higher). </p> <p>There was no mean change in FEV<sub>1</sub> (L) after tiotropium 5 µg (mean difference = zero (0.1 L lower to 0.1 L higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (2.5 µg dose)</p> <p>38 (5 µg dose)</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference was seen between tiotropium and placebo at either dose or in either age group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported outcomes: quality of life (measured by CFQ‐R)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no differences in CFQ‐R domain scores after 12 weeks of treatment with tiotropium. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>974<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were given for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events after tiotropium 5.0 µg</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>755 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>725 per 1000</b><br/>(664 to 785) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.88 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further trial reported adverse events over 28 days and so we have not combined the results. There were no significant differences between tiotropium at 2.5 or 5 µg and placebo with regard to adverse events (P = 0.97, P = 0.91 respectively). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary exacerbations: participants reporting ≥1 pulmonary exacerbation during the trial period after tiotropium 5 µg </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(2 to 6 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> (0.32 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>805<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The overall effect was not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other measures of lung function: mean change from baseline in FEV<sub>1</sub> AUC<sub>0-4h</sub> (% predicted) after tiotropium 5.0 µg </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> ranged across placebo groups from<br/>‐1.74% predicted to 0.87% predicted. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change across both age groups in the tiotropium 5.0 µg groups was 2.59% higher (1.28 to 3.89) than placebo. </p> <p>The mean change across the 5 to ≤ 11 year age group was 1.97% higher (‐0.57 to 4.52) than placebo. </p> <p>The mean change across the ≥ 12 year age group was 2.83% higher (1.37, 4.30) than placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>770</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In both trials, a greater effect was seen in the ≥ 12 year age group than the younger age group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other measures of lung function: mean change from baseline in trough FEV<sub>1</sub> (% predicted) after tiotropium 5.0 µg </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> ranged across placebo groups from ‐1.44% predicted to 0.72% predicted. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change across both age groups in the tiotropium 5.0 µg groups was 1.81% higher (0.44 to 3.18) than placebo. </p> <p>The mean change across the 5 to ≤ 11 year age group was 0.88% higher (‐1.76 to 3.53) than placebo. </p> <p>The mean change across the ≥ 12 year age group was 2.325 higher (0.81, 3.82) than placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>772</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFQ‐R</b> : cystic fibrosis questionnaire (revised); <b>CI</b> : confidence interval; <b>FEF<sub>25-75</sub> </b> : mid peak expiratory flow; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>FVC</b> : forced vital capacity; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once due to risk of bias as methods of blinding were not described.</p> <p>2. Downgraded once due to imprecision due to a small sample size, low event rates and only one trial contributing data. </p> <p>3. Downgraded twice due to imprecision as the data weren't presented and unclear risk of bias from lack of information. </p> <p>4. Downgraded once due to imprecision due to low event rates.</p> <p>5. Downgraded once due to indirectness: this is not a measure used routinely in the clinical area. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012102-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012102-sec-0009"></div> <p>Please refer to the glossary for an explanation of terms used (<a href="./appendices#CD012102-sec-0121">Appendix 1</a>). </p> <section id="CD012102-sec-0010"> <h3 class="title" id="CD012102-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is the most common life‐limiting autosomal recessive inherited disease in white populations; it affects approximately 70,000 children and adults worldwide (<a href="./references#CD012102-bbs2-0029" title="CF Foundation. About Cystic Fibrosis. www.cff.org/AboutCF/ (accessed 08 June 2015).">CF Foundation 2015</a>), with a rate of one in 2500 newborns in the UK (<a href="./references#CD012102-bbs2-0042" title="TobiasES , ConnorM , Ferguson-SmithM . Essentials : Essential Medical Genetics. 6th edition. Hoboken, NJ, USA: Wiley-Blackwell, 2011.">Tobias 2011</a>). It was once considered a childhood disease, but with improvements in diagnosis and treatments, many people with CF are living well into adulthood. In 2012, data from the UK Cystic Fibrosis National Registry reported a median predicted survival of 43.5 years (<a href="./references#CD012102-bbs2-0043" title="UK CF Trust. UK CF registry annual report 2013. www.cysticfibrosis.org.uk/media/598466/annual-data-report-2013-jul14.pdf (accessed 10 June 2015).">UK CF Trust 2014</a>). </p> <p>CF is a multifaceted disease affecting the gastrointestinal, pulmonary and endocrine systems. The condition is caused by a faulty gene which encodes a protein called the cystic fibrosis transmembrane conductance regulator (CFTR). This protein regulates chloride, and so water, regulation across the cell membrane. Dysfunction leads to thickened, dehydrated mucus. In the lungs this results in chronic airway infection which can progress to bronchiectasis (damage to the airways), hypoxaemia (low oxygen levels) and hypercarbia (high carbon dioxide levels) (<a href="./references#CD012102-bbs2-0037" title="O'SullivanBP , FreedmanSD . Cystic fibrosis. Lancet2009;373(9678):1891-904. [DOI: 10.1016/S0140-6736(09)60327-5]">O'Sullivan 2009</a>). Pulmonary disease causes considerable morbidity and accounts for almost 70% of CF‐related deaths (<a href="./references#CD012102-bbs2-0028" title="CF Foundation Patient Registry. Annual data report to the center directors 2013. www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf (accessed 14 October 2015).">CF Foundation 2014</a>). </p> <p>Adults and children with CF experience coughing, wheezing and shortness of breath due to reduced mucociliary clearance of the thickened mucus. Interventions to improve lung health include bronchodilators, hypertonic saline, dornase alfa, physiotherapy for airway clearance and antibiotics (oral, intravenous and aerosolised). In 2009, the Cystic Fibrosis Foundation Pulmonary Therapies Committee updated their guidelines for the maintenance of lung health and specifically looked at the evidence for each of these therapies (<a href="./references#CD012102-bbs2-0035" title="Mogayzel PJ Jr, NaureckasET , RobinsonKA , MuellerG , HadjiliadisD , HoagJB , et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. American Journal of Respiratory &amp; Critical Care Medicine2013;187(7):680-9.">Mogayzel 2013</a>). Bronchodilators are prescribed for over 80% of people with CF and many report that they help to alleviate the symptoms of wheezing and shortness of breath (<a href="./references#CD012102-bbs2-0030" title="ColomboJL . Long-acting bronchodilators in cystic fibrosis. Current Opinion in Pulmonary Medicine2003;9(6):504-8.">Colombo 2003</a>). </p> <p>Concomitant asthma is also a problem for some individuals with CF and obtaining a diagnosis is often difficult. Obstruction of the airways and wheezing in CF share common features with asthma including airway mucosal oedema due to chronic inflammation and infection, obstruction of the airways by abnormally viscid secretions, stimulation of autonomic nerve fibres, airway smooth muscle contraction and airway collapse. In some individuals there may be a tendency to atopic asthma, which contributes to these symptoms (<a href="./references#CD012102-bbs2-0022" title='Balfour-Lynn IM , Elbourn JS . "CF Asthma": what is it and what do we do about it?Thorax2002;57(8):742-8.'>Balfour‐Lynn 2002</a>). There is no gold standard definition of asthma in children and the diagnosis is based on clinical symptoms (wheeze, breathlessness, chest tightness and cough) and variable airflow obstruction (<a href="./references#CD012102-bbs2-0026" title="British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. A national clinical guideline.. http://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016 (accessed November 2016).">BTS 2016</a>). Airway hyper‐responsiveness and airway inflammation are also described as components of the disease. Bronchodilator responsiveness is widely used in the diagnosis of asthma, but its role in CF is less clear cut due to the variability in lung function measures. In CF, the mechanisms of airway inflammation differ from asthma and result in progressive non‐reversible airflow obstruction (<a href="./references#CD012102-bbs2-0022" title='Balfour-Lynn IM , Elbourn JS . "CF Asthma": what is it and what do we do about it?Thorax2002;57(8):742-8.'>Balfour‐Lynn 2002</a>). </p> <p>Although CF and atopy, with or without asthma, may co‐exist in some individuals, it is not known if these individuals will derive a greater benefit from the use of inhaled bronchodilators. </p> </section> <section id="CD012102-sec-0011"> <h3 class="title" id="CD012102-sec-0011">Description of the intervention</h3> <p>Both short‐acting and long‐acting inhaled bronchodilators are used to treat of CF pulmonary symptoms, to open the airways and help with airway clearance. They may also be prescribed to relieve symptoms attributable to CF asthma as an adjunct to physiotherapy, to help improve sputum clearance and to prevent bronchoconstriction‐related symptoms during nebulised therapy. Short‐acting and long‐acting inhaled bronchodilators differ in their duration of action. Short‐acting bronchodilators are used mainly for the relief of sudden attacks of breathlessness, they take effect within minutes and effects typically last four to six hours for beta‐2 agonists and six to eight hours for muscarinic antagonists (<a href="./references#CD012102-bbs2-0027" title="CazzolaM , PageCP , CalzettaL , MateraMG . Pharmacology and therapeutics of bronchodilators. Pharmacological Reviews2012;64(3):450-504.">Cazzola 2012</a>). Long‐acting bronchodilators are used for a longer‐lasting effect and maintenance (as a preventer inhaler). Whilst they too take effect within a few minutes, the maximum bronchodilation may not occur for several hours and the duration of action is at least 12 hours (<a href="./references#CD012102-bbs2-0027" title="CazzolaM , PageCP , CalzettaL , MateraMG . Pharmacology and therapeutics of bronchodilators. Pharmacological Reviews2012;64(3):450-504.">Cazzola 2012</a>). The bronchodilation effect of a muscarinic antagonist bronchodilator, tiotropium lasts for over 24 hours (<a href="./references#CD012102-bbs2-0023" title="BarnesPJ . The pharmacological properties of tiotropium. Chest2000;117(2 Suppl):63S-6S.">Barnes 2000</a>). </p> <p>This review will focus on long‐acting bronchodilators, which can be classified into two types: </p> <p> <ol id="CD012102-list-0001"> <li> <p>long‐acting beta‐2 agonists (e.g. salmeterol, formoterol);</p> </li> <li> <p>long‐acting muscarinic antagonists (LAMAs) (e.g. tiotropium, aclidinium).</p> </li> </ol> </p> <p>While these different agents have the same clinical effect of causing the smooth muscle of the airways to relax, it is not appropriate to group them together as they have different properties and different modes of action. Both beta‐2 agonists and muscarinic antagonists are delivered into the lungs via either a dry powder device or a metered dose inhaler (with or without the use of a large volume spacer to increase deposition in the lungs) or as an aerosol via a nebuliser (with or without additional oxygen), which usually requires a larger starting dose but delivers an equivalent dose to the lungs. </p> </section> <section id="CD012102-sec-0012"> <h3 class="title" id="CD012102-sec-0012">How the intervention might work</h3> <p>Both beta‐2 agonists and muscarinic antagonists work by allowing the muscles in the lungs to relax, thus opening the airways and allowing increased air entry. Inhaled bronchodilators also have effects on mucociliary clearance (<a href="./references#CD012102-bbs2-0030" title="ColomboJL . Long-acting bronchodilators in cystic fibrosis. Current Opinion in Pulmonary Medicine2003;9(6):504-8.">Colombo 2003</a>). </p> <section id="CD012102-sec-0013"> <h4 class="title">Long‐acting beta‐2 agonists</h4> <p>A long‐acting beta‐2 agonist reaches the beta‐2 receptors through the cell membrane. It has a lipophilic tail which binds to a receptor near the beta‐2 adrenoceptor, so it stays bound for longer, and thus has a longer duration of action than short‐acting beta‐2 agonists. The actions of beta‐2 agonists are mediated by cyclic adenosine monophosphate (cAMP). Increased intracellular cAMP increases the activity of cAMP‐dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to smooth muscle relaxation and bronchodilation. Formoterol has an onset of action which is more rapid; both formoterol and salmeterol cause bronchodilation which lasts for a minimum of 12 hours (<a href="./references#CD012102-bbs2-0030" title="ColomboJL . Long-acting bronchodilators in cystic fibrosis. Current Opinion in Pulmonary Medicine2003;9(6):504-8.">Colombo 2003</a>). </p> </section> <section id="CD012102-sec-0014"> <h4 class="title">Long‐acting muscarinic antagonists</h4> <p>Muscarinic antagonists affect the muscles around the bronchi and stop the muscles from tightening when they are irritated. Muscarinic antagonists bind to muscarinic receptors on airway smooth muscle and prevent action of acetylcholine via cyclic guanosine monophosphate (cGMP). This also results in reduced mucus secretion. They take effect in approximately 20 minutes and last for 24 hours, which means that these agents are only taken once a day for maintenance (<a href="./references#CD012102-bbs2-0021" title="American Thoracic Society. What are anticholinergic medications?www.thoracic.org/copd-guidelines/for-patients/what-kind-of-medications-are-there-for-copd/what-are-anticholinergic-medications.php (accessed 23 June 2015).">ATS 2015</a>). </p> </section> <section id="CD012102-sec-0015"> <h4 class="title">Measurement of effect</h4> <p>Lung function in people with CF is commonly measured using spirometry measures such as forced expiratory volume in one second (FEV<sub>1</sub>), peak expiratory flow rate (PEFR) and forced vital capacity (FVC). While FEV<sub>1</sub> remains the main measure of change caused by an intervention in CF, reversibility (a change in FEV<sub>1</sub> of 12% to 15%) is the standard by which change caused by bronchodilators is measured (<a href="./references#CD012102-bbs2-0038" title="PellegrinoR , ViegiG , BrusascoV , CrapoRO , BurgosF , CasaburiR , et al. Interpretative strategies for lung function tests. European Respiratory Journal2005;26:948-68.">Pellegrino 2005</a>). These tests provide information for monitoring of lung function, but they require co‐operation from the individual and a good technique. It has been noted that the results of such tests may be less reliable in children under the age of five to seven years (<a href="./references#CD012102-bbs2-0033" title="KanengiserS , DozorAJ . Forced expiratory maneuvers in children aged 3 to 5 years. Pediatric Pulmonology1994;18(3):144-9.">Kanengiser 1994</a>). </p> <p>Whilst the effect of bronchodilators can be measured by comparing the pre‐ and immediately post‐dose lung function, with long‐acting bronchodilators we are interested in the effect over time. We would be looking for an increase in FEV<sub>1</sub> for example, with every dose and a gradual increase in the average FEV<sub>1</sub> over time. Other effects include changes in quality of life (QoL), participant‐reported symptoms, adverse events and exacerbations. </p> </section> </section> <section id="CD012102-sec-0016"> <h3 class="title" id="CD012102-sec-0016">Why it is important to do this review</h3> <p>The updated CF Foundation Pulmonary Clinical Practice Guidelines report that there is insufficient evidence in favour of or against the use of inhaled muscarinic antagonists and the chronic use of beta‐2 receptor agonists to improve lung function or quality of life (<a href="./references#CD012102-bbs2-0035" title="Mogayzel PJ Jr, NaureckasET , RobinsonKA , MuellerG , HadjiliadisD , HoagJB , et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. American Journal of Respiratory &amp; Critical Care Medicine2013;187(7):680-9.">Mogayzel 2013</a>). A previous Cochrane Review looked at the effectiveness of both short‐ and long‐acting inhaled bronchodilators for CF (<a href="./references#CD012102-bbs2-0044" title="HalfhideC , EvansHJ , CourielJ . Inhaled bronchodilators for cystic fibrosis. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD003428. [DOI: 10.1002/14651858.CD003428.pub2]">Halfhide 2005</a>). More than a decade on from this original review, it is important to update this review and search for more recent trials of long‐acting inhaled bronchodilators to provide a clearer picture of their efficacy in terms of lung function but also in terms of their effect on QoL and adverse events. </p> <p>Following the initial version of this review focussing on long‐acting inhaled bronchodilators it has been agreed not to undertake any further updates due to the lack of research in this area. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012102-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012102-sec-0017"></div> <p>This review aims to evaluate long‐acting inhaled bronchodilators in children and adults with CF in terms of clinical outcomes and safety. If possible, we aimed to assess the optimal drug and dosage regimen. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012102-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012102-sec-0018"></div> <section id="CD012102-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012102-sec-0020"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs). We assessed quasi‐RCTs on their merit using the Cochrane risk of bias tool; if the method of allocation was described (e.g. alternate allocation, date of birth or medical record number) and both reviewer authors were satisfied that the groups were similar at baseline, we included them. </p> <p>In a post hoc change we excluded cross‐over trials; due to the carry‐over effects of long‐acting medication, it is not possible to ensure that the groups are the same at baseline. </p> <p>We included trials published as full texts. If there was only an abstract available for a trial, we included it if results were presented. If no results were presented in either the abstract or on any trials registry sites, we classified this trial as 'Awaiting assessment' until more information was available. Similarly with unpublished trials, if a trial met our inclusion criteria and quality assessment, then we included it. </p> </section> <section id="CD012102-sec-0021"> <h4 class="title">Types of participants</h4> <p>Children and adults with CF diagnosed by sweat test or genetic testing, with all stages and severity of lung disease and with or without concomitant asthma. </p> </section> <section id="CD012102-sec-0022"> <h4 class="title">Types of interventions</h4> <p>Long‐acting inhaled bronchodilators delivered via any device and at any dose, frequency or duration. For this review we considered the term 'inhaled' to include the use of pressurised metered dose inhalers (MDIs) with or without a large‐volume spacer, dry powder devices and nebulisers. We included both types of long‐acting bronchodilators which have a duration of action of at least 12 hours: </p> <p> <ul id="CD012102-list-0002"> <li> <p>beta‐2 agonists, e.g. salmeterol, formoterol;</p> </li> <li> <p>muscarinic antagonists, e.g. tiotropium, aclidinium.</p> </li> </ul> </p> <p>We did not consider combined inhalers (with inhaled steroids or another bronchodilator) or short‐acting inhaled bronchodilators (e.g. salbutamol, ipratropium bromide). </p> <p>The comparator was an inhaled placebo, another long‐acting bronchodilator (or the same drug at a different dose) or usual treatment. It is possible that usual treatment may include a short‐acting bronchodilator and therefore participants randomised to the long‐acting bronchodilator may also be taking a short‐acting bronchodilator. We took this into consideration by looking at the inclusion and exclusion criteria of individual trials. </p> </section> <section id="CD012102-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD012102-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012102-list-0003"> <li> <p>Change in FEV<sub>1</sub> from baseline (L and per cent (%) predicted) </p> </li> <li> <p>Participant‐reported outcomes including QoL using standardised and validated QoL scores (e.g. CFQ‐R (<a href="./references#CD012102-bbs2-0039" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>)) and symptom scores (e.g. Respiratory and Systemic Symptoms Questionnaire (RSSQ), Respiratory Symptom Score (RSS) (<a href="./references#CD012102-bbs2-0031" title="GossCH , QuittnerAL . Patient-reported outcomes in cystic fibrosis. Proceedings of the American Thoracic Society2007;4:378-6.">Goss 2007</a>)) </p> </li> <li> <p>Adverse effects (especially those associated with long‐acting inhaled bronchodilators i.e. for beta‐2 agonists tremor, nervous tension, headache, peripheral dilatation and palpitation, increased heart rate, dry mouth, increased wheeze and shortness of breath; for LAMAs dry mouth, gastrointestinal motility disorder (constipation and diarrhoea), nausea, gastro‐oesophageal reflux disease, dysphagia, tachycardia) </p> <ol id="CD012102-list-0004"> <li> <p>frequency of adverse effects</p> </li> <li> <p>severity of adverse effects, e.g. mild or moderate or severe (where it has been reported)</p> </li> </ol> </li> </ol> </p> </section> <section id="CD012102-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012102-list-0005"> <li> <p>Number of exacerbations of respiratory symptoms as defined by</p> <ol id="CD012102-list-0006"> <li> <p>individual clinicians or the use of a scoring system such as the RSSQ, or both</p> </li> <li> <p>the need for hospitalisation or antibiotics or both</p> </li> </ol> </li> <li> <p>Time to first exacerbation</p> </li> <li> <p>Other measures of lung function</p> <ol id="CD012102-list-0007"> <li> <p>peak expiratory flow rate (PEFR) (L per minute and % predicted)</p> </li> <li> <p>measures of bronchial hyper‐responsiveness and bronchodilator responsiveness, e.g. reversibility, methacholine challenge or equivalent (histamine or mannitol), exercise testing </p> </li> <li> <p>forced expiratory flow between 25% and 75% of expiratory flow (FEF <sub>25-75</sub>) (L per second and % predicted) </p> </li> <li> <p>forced vital capacity (FVC) (L and % predicted)</p> </li> <li> <p>any other measurements of lung function that are relevant, e.g. trough FEV<sub>1</sub>, lung clearance index (LCI) and area under the curve (AUC) </p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD012102-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not restrict the searches by language, year or publication status.</p> <section id="CD012102-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Group's Cystic Fibrosis Trials Register using the terms: bronchodilator AND (inhaled OR *stated). </p> <p>The Cystic Fibrosis Trials Register has been compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the <i>Cochrane Library</i> ), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective Handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work has been identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cystic Fibrosis and Genetic Disorders Group <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of the latest search: 10 October 2017.</p> <p>We also carried out a separate search of Embase from inception using the search terms cystic fibrosis AND bronchodilator AND inhaled (<a href="./appendices#CD012102-sec-0122">Appendix 2</a>). </p> <p>Date of the latest search: 11 October 2017.</p> <section id="CD012102-sec-0028"> <h5 class="title">Grey literature</h5> <p>We searched Open Grey using the search terms "bronchodilator*" AND "cystic fibrosis" (<a href="http://www.opengrey.eu/" target="_blank">http://www.opengrey.eu/</a>). There were no resulting papers to add to the main search results for screening by two reviewer authors. </p> <p>Date of the latest search: 16 October 2017.</p> </section> <section id="CD012102-sec-0029"> <h5 class="title">Clinical trial registries</h5> <p>We searched the clinical trial registries ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), the International Standard Randomised Controlled Trial Number (ISRCTN) registry (www.isrctn.com) and the WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) for any ongoing and or unpublished trials using the terms " bronchodilator" and "cystic fibrosis". We also included drug names (formoterol, salmeterol, tiotropium and alcidium) to increase sensitivity of the search where trials may only list the drug name. </p> <p>Date of the latest search (Clinical Trials.gov; ISRCTN): 11 October 2017.</p> <p>Date of latest search (ICTRP): 13 November 2017.</p> <p>We searched the AstraZeneca Clinical Trials Website (<a href="https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Search" target="_blank">astrazenecagrouptrials.pharmacm.com/ST/Submission/Search</a>) on 16 October 2017. </p> </section> </section> <section id="CD012102-sec-0030"> <h4 class="title">Searching other resources</h4> <section id="CD012102-sec-0031"> <h5 class="title">Reference Lists</h5> <p>We searched reference list of all included trials to identify any further relevant trials. </p> <p>Date of the latest search: 25 August 2016.</p> </section> <section id="CD012102-sec-0032"> <h5 class="title">Correspondence</h5> <p>We contacted the pharmaceutical companies Allen &amp; Hanburys (A&amp;H) (which is part of GlaxoSmithKline (GSK)) and Novartis for information on any unpublished trials or relevant research. </p> <p>Date of correspondence: 02 April 2016.</p> <p>Where papers were only in abstract form, we contacted the author to try and obtain a full paper or more information on the trial. Date of contact (Turchetta) 12 July 2017. </p> </section> </section> </section> <section id="CD012102-sec-0033"> <h3 class="title" id="CD012102-sec-0033">Data collection and analysis</h3> <section id="CD012102-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Once we had the complete list of identified references, one review author (SS) checked for duplicates and removed them. Both authors (SS and CE) then reviewed all titles and abstracts and discarded references which clearly didn't meet the inclusion criteria. We attempted to resolve any disagreements by discussion, but where a decision could not be reached then we asked the managing editor of the review group to mediate until we could reach a final decision. Once we had discarded trials on the basis of title and abstract, we obtained full copies of the remaining references and screened these using a standardised screening form customised for this review. </p> <p>We considered trials in any language, but all the trials identified were in English. We have presented the results of the searches in a flow chart (<a href="#CD012102-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012102-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012102-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012102-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Both review authors independently extracted data using a specially designed data extraction form developed by the Cochrane Cystic Fibrosis and Genetic Disorders Review Group and adapted to this review. We collected data on: </p> <p> <ul id="CD012102-list-0008"> <li> <p>participant characteristics;</p> </li> <li> <p>trial characteristics and trial design;</p> </li> <li> <p>intervention and comparator;</p> </li> <li> <p>outcome data ‐ we reported data for each outcome separately.</p> </li> </ul> </p> <p>One author (SS) checked the independent data extraction forms for discrepancies and where these could not be resolved by discussion, the Managing Editor of the review group (NJ) arbitrated. </p> <p>One author (SS) entered the doubly extracted data into Review Manager software for analysis (<a href="./references#CD012102-bbs2-0040" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We entered and presented data for beta‐2 agonists and muscarinic antagonist bronchodilators separately due to their different properties and modes of action. We planned to carry out the following comparisons: </p> <p> <ul id="CD012102-list-0009"> <li> <p>beta‐2 agonists versus placebo or usual treatment or another beta‐2 agonist;</p> </li> <li> <p>LAMAs versus placebo or usual treatment or another muscarinic antagonist agent; and</p> </li> <li> <p>beta‐2 agonists versus LAMAs.</p> </li> </ul> </p> <p>We planned to present outcome data at up to seven days, over seven days and up to 28 days, over 28 days and up to three months, over three months and up to six months, over six months and up to a year and annually thereafter. </p> </section> <section id="CD012102-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the risk of bias tool as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess the risk of bias across six domains (sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other potential sources of bias) (<a href="./references#CD012102-bbs2-0032" title="HigginsJPT , AltmanDG , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Both authors assessed the included trials for risk of bias independently and we compared our results. Again, any discrepancies were resolved by discussion and where this did not lead to agreement, we involved a third person (Managing Editor of the review group (NJ)). </p> <p>Where the trial described the methods of randomisation and allocation, including the concealment of the allocation sequence from the researchers, and both reviewers deemed these to be adequate, then we ranked the trial as having a low risk of bias for this domain. Where these were inadequate, we ranked the trial as being at a high risk and where it was unclear from the description given, then we ranked it as having an unclear risk of bias. </p> <p>Similarly for blinding, we looked at the method used and who was blinded to determine the risk of bias. We deemed trials to have a low risk of bias if it was double blinded with participants, investigators and outcome assessors being blind to the treatment that was allocated. Where a trial was only partially blinded, the risk of bias was considered to be higher and where the trial was unblinded, the risk was deemed to be high. </p> <p>We extracted information on missing data and how the investigators recorded participant withdrawals and loss to follow‐up. We also looked at whether missing data were equally distributed between the intervention and control groups. If both review authors agreed that missing data had been accounted for adequately, then we judged the trial to be at a low risk of bias. We recorded the trial as having a high risk of bias if the missing data were not reported adequately and recorded it as having an unclear risk of bias if we were unable to see how the missing data had been reported. Two authors assessed each included trial to determine whether the investigators used an intention‐to‐treat (ITT) analysis and again, once we reached an agreement, we ranked the trials as being at a high, low or unclear risk of bias. </p> <p>If the trial investigators reported all outcomes in the paper, the two review authors recorded a low risk of bias from selective reporting. If there were outcomes stated as being measured where the investigators do not report results, the review authors ranked the paper as being at high risk. If it was unclear to both review authors whether all outcomes were reported, then we stated this and ranked it as unclear for this domain. We searched for trial protocols to be able to assess outcome reporting. If the protocol could be found, we assessed outcome reporting based on a comparison between the methods section of the full published paper and the results section. </p> <p>Both review authors looked for any other potential sources of bias in the included trials and recorded what they found. If neither author could find any other source of bias, then we ranked the trial as having a low risk for this domain and high risk if the opposite was true. </p> <p>We presented the results of the risk of bias assessment both individually and in a summary table. </p> </section> <section id="CD012102-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We reported measures of treatment effect for each outcome and for each type of long‐acting bronchodilator separately. </p> <p>For dichotomous data (adverse effects), we calculated a pooled estimate of the treatment effects for each outcome across trials using risk ratio (RR) and 95% confidence intervals (CIs) where appropriate. </p> <p>For continuous data (FEV<sub>1</sub>, FVC, FEF<sub>25-75%</sub>, PEFR, LCI, QoL and symptom scores) we recorded the mean change and standard deviation (SD) from baseline for each group. We calculated a pooled estimate of treatment effect using the mean difference (MD) and 95% CIs where it was possible to combine trial outcome data. It was not possible to combine data from trials where the outcomes and time points were different. In future updates where trials use different units of measurement or measurement scales for reporting the same outcome (e.g. QoL) we will use the standardised mean difference (SMD) to report the results. Where trials reported only a pre‐intervention mean (SD) and post‐intervention mean (SD) then we calculated the mean change but not the SD of the change. These results have been reported narratively. </p> <p>For FEV<sub>1</sub> we looked for a change of over 12% for a meaningful effect and a change of over 15% in FEF<sub>25-75</sub> (<a href="./references#CD012102-bbs2-0024" title="Barreiro TJ , PerilloI . An approach to interpreting spirometry. American Family Physician2004;69(5):1107-14.">Barreiro 2004</a>). </p> <p>No time‐to‐event data was reported in any of the trials but if this type of data is reported in future trials, we will express the intervention effect as a hazard ratio (HR) with 95% CIs using the generic inverse variance method. </p> </section> <section id="CD012102-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>In multi‐arm trials, where the data fell into more than one comparison, each treatment arm was analysed separately against placebo and where appropriate included in a meta‐analysis. In future updates, if the two active treatment arms are of the same type of long‐acting bronchodilator, but employ a different drug or dose, we will combine them against the placebo arm to look at the effect of the different type of long‐acting bronchodilator rather than an individual drug. </p> <p>Cross‐over trials are not eligible for inclusion due to the carry‐over effects of long‐acting medication. </p> <p>We planned to carry out a subgroup analysis to look at the effect of individual drugs if there was heterogeneity between trials looking at different types of long‐acting bronchodilator (<a href="#CD012102-sec-0043">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> <section id="CD012102-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to request additional data from the trial author(s) if there were insufficient data in the published paper or uncertainty about data we were able to extract from the included trials. </p> <p>We assessed the extent to which trial authors have employed an ITT analysis and we reported the numbers of participants who dropped out of each arm of the trial, where possible. </p> </section> <section id="CD012102-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>Where there were trials reporting the same outcomes which we are able to include in a meta‐analysis, we assessed the level of heterogeneity using the I² statistic. We looked at the overlap of the CIs on the forest plots to gauge the significance of the I² value. </p> <p>We based our definitions of different levels of heterogeneity on the levels described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>: </p> <p> <ul id="CD012102-list-0010"> <li> <p>low (might not be important) = 0% to 40%;</p> </li> <li> <p>moderate = 30% to 60%;</p> </li> <li> <p>substantial = 50% to 90%; and</p> </li> <li> <p>considerable = 75% to 100%.</p> </li> </ul> </p> <p>The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> states that this is a rough guide because the importance of inconsistency depends on several factors (<a href="./references#CD012102-bbs2-0032" title="HigginsJPT , AltmanDG , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD012102-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to generate a funnel plot to attempt to identify any publication bias in the included trials (<a href="./references#CD012102-bbs2-0032" title="HigginsJPT , AltmanDG , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>); however, there were less than 10 included trials and therefore, insufficient trials to conduct this analysis. We attempted to identify any selective reporting in the included publications, by comparing the trial protocols with the final papers and by careful examination of the trial publications and consideration of reporting of both positive and negative effects of the intervention. Where trial protocols weren't available, we compared the outcomes reported in the results section against the methods section of the paper. We extracted information on the sponsors, sources of funding and competing interests of the authors to determine the role of external bias being introduced. To minimise publication bias, we searched trial registries and contacted pharmaceutical companies for any unpublished data. </p> </section> <section id="CD012102-sec-0042"> <h4 class="title">Data synthesis</h4> <p>Where we were able to combine trials in a meta‐analysis, we used the data from the selected trials to generate forest plots using the Review Manager software (<a href="./references#CD012102-bbs2-0040" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We carried out separate meta‐analyses for the two different types of long‐acting bronchodilators. We examined the level of heterogeneity to determine which type of analysis model to use. If there was low heterogeneity (less than 40%) then we used a fixed‐effect model and if the I² statistic was greater than 40% then we used a random‐effects model to summarize the data. </p> </section> <section id="CD012102-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If there was greater than 40% heterogeneity in the included trials, we planned to undertake subgroup analyses to look at: </p> <p> <ul id="CD012102-list-0011"> <li> <p>severity of lung disease (based on a classification by Pellegrino using values for FEV<sub>1</sub> % predicted, we will use the following definitions: mild (over 70%); moderate (60% to 69%); moderately severe (50% to 59%); severe (35% to 49%); very severe (below 35%) (<a href="./references#CD012102-bbs2-0038" title="PellegrinoR , ViegiG , BrusascoV , CrapoRO , BurgosF , CasaburiR , et al. Interpretative strategies for lung function tests. European Respiratory Journal2005;26:948-68.">Pellegrino 2005</a>)); </p> </li> <li> <p>presence of asthma;</p> </li> <li> <p>presence of measured airway reversibility (based on reversibility or methacholine challenge or exercise testing); </p> </li> <li> <p>age (children under 18 versus adults aged 18 or over);</p> </li> <li> <p>the effect of individual drugs.</p> </li> </ul> </p> <p>There were insufficient trials with comparable outcomes to be able to carry out subgroup analyses of severity of lung disease, presence of asthma or presence of measured airway reversibility. As there was only one drug in each of the comparisons it wasn't possible to carry out a subgroup analysis on the effect of individual drugs. </p> <p>It was possible to look at the effect of age for two of the trials looking at tiotropium.</p> </section> <section id="CD012102-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>Where we have carried out a meta‐analysis, we planned to carry out sensitivity analyses to look at the effect of the risk of bias findings and to look at the effect of adding in and taking out trials where there was high risk of bias. This was not possible due to there not being enough trials included in a meta‐analysis. </p> </section> <section id="CD012102-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We have reported summary of findings information where there was at least one trial assessing our chosen outcomes for the comparison of beta‐2 agonists versus control and muscarinic antagonists versus control and for the outcomes: </p> <p> <ul id="CD012102-list-0012"> <li> <p>change in FEV<sub>1</sub> from baseline; </p> </li> <li> <p>participant‐reported outcomes (QoL);</p> </li> <li> <p>adverse events;</p> </li> <li> <p>pulmonary exacerbations;</p> </li> <li> <p>other measures of lung function.</p> </li> </ul> </p> <p>For each outcome we have reported the illustrative risk with and without the intervention, magnitude of effect (RR or MD), numbers of trials and participants addressing each outcome and a grade of the overall quality of the body of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) with comments (<a href="./references#CD012102-bbs2-0041" title="SchunemannHJ , FretheimA , OxmanAD . Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation. Health Research Policy &amp; Systems2006;4:25.">Schunemann 2006</a>). </p> <p>We have created separate tables for each separate comparison we present.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012102-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012102-sec-0046"></div> <section id="CD012102-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD012102-sec-0048"> <h4 class="title">Results of the search</h4> <p>The searches identified 195 unique references which were filtered by two authors (SS, CE) on title and abstract resulting in 40 references (20 trials) which were screened on full text. We have included four trials (12 references) with 1082 participants which met our inclusion criteria and have excluded 16 trials (28 references) with reasons (<a href="./references#CD012102-bbs1-0002" title="">Excluded studies</a>). No ongoing trials were identified and no trials are awaiting classification (see PRISMA flow chart <a href="#CD012102-fig-0001">Figure 1</a>). </p> </section> <section id="CD012102-sec-0049"> <h4 class="title">Included studies</h4> <p>We identified four trials (12 references) which were eligible for inclusion; one trial examined the effects of the beta‐2 agonist salmeterol (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>) and the remaining three trials examined the effects of the muscarinic antagonist tiotropium (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). One trial was reported only in abstract form (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>), whilst the remaining three trials were reported as full‐text articles (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). The characteristics of the included trials are presented in the tables (<a href="./references#CD012102-sec-0135" title="">Characteristics of included studies</a>). </p> <section id="CD012102-sec-0050"> <h5 class="title">Beta‐2 agonists</h5> <p>One trial (16 participants) looked at the effects of inhaled long‐acting beta‐2 agonists (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> <section id="CD012102-sec-0051"> <h6 class="title">Trial design</h6> <p>This trial was of parallel design and was carried out over one month (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). The trial report did not state where it was conducted, although all the authors listed on the abstract were affiliated to the same children's hospital in Italy (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> </section> <section id="CD012102-sec-0052"> <h6 class="title">Participants</h6> <p>The trial had small numbers of participants with only 16 young people being included (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). The participants were children with a mean (SD) age of 13.9 (3.1) years and a range of 10 to 17 years. The gender split was weighted towards males (68.7%) (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). Disease severity at baseline was reported as a mean (SD) FEV<sub>1</sub> % predicted at baseline of 72% (19) (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). The trial did not state whether the participants had asthma. </p> </section> <section id="CD012102-sec-0053"> <h6 class="title">Interventions</h6> <p>The intervention in this trial was the beta‐2 agonist, salmeterol which was given twice daily (two puffs) (actual dose not stated) and the comparator used was no treatment (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> </section> <section id="CD012102-sec-0054"> <h6 class="title">Outcomes</h6> <p>The trial reported on change from baseline in FEV<sub>1</sub> to end of treatment (a month of treatment), although no data (only a significance level) were reported in the Turchetta abstract. They also reported on FVC but again, only the significance level was given. The trial did not report on adverse events or participant‐reported outcomes, pulmonary exacerbations or any other measures of lung function (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> </section> </section> <section id="CD012102-sec-0055"> <h5 class="title">Muscarinic antagonists</h5> <p>Three trials examined the effects of long‐acting muscarinic antagonist bronchodilators (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). The three trials with their associated references reported on phase I (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>), phase II (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>) and phase III (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>) of a randomised, multicentre trial carried out across Europe, USA and Australia. </p> <section id="CD012102-sec-0056"> <h6 class="title">Trial design</h6> <p>The three trials were parallel in design (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>), one of these being a step‐wise dose escalation trial (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>). and were measured over one month (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>) and 12 weeks (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> </section> <section id="CD012102-sec-0057"> <h6 class="title">Participants</h6> <p>The three trials had numbers of participants ranging from 92 (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>) to 510 (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>) and included both children and adults with an age range of five months (0.4 years) to 70.5 years (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). The proportion of male participants ranged from 54% (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>) to 56% (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Disease severity at baseline was measured in all three trials as % predicted FEV<sub>1</sub>. Mean (SD) FEV<sub>1</sub> % predicted ranged from 89.8% (17.8%) (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>) to 98.7% (12.8%) (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>) in the participants aged 11 or younger; and 68.8% (23.3%) to 74.4% (21.4%) (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>) in participants aged 12 or over. None of the trials stated whether the participants had asthma. </p> </section> <section id="CD012102-sec-0058"> <h6 class="title">Interventions</h6> <p>All three trials examined the effects of tiotropium bromide in varying doses and schedules. The dose administered ranged from 2.5 µg (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>) to 10.0 µg (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>) via Respimat Soft mist inhaler. The Bradley trial administered a single dose of tiotropium at one time point (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>), one trial administered treatment twice a day (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>) and the third trial looked at the effects of a single dose and multiple doses (once daily for 28 days) within the same trial report (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>). In this review we only included the multiple dose trial. In both the Bradley and Ratjen trials, participants continued their regular treatment which in some cases included a short‐acting bronchodilator. In the Bradley trial 61.3 % of the placebo group were taking short‐acting bronchodilators, 54.2 % of the 2.5 ųg group and 63.1 % of the 5 ųg group (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> </section> <section id="CD012102-sec-0059"> <h6 class="title">Outcomes</h6> <p>Only one of the three trials reported on a measure of FEV<sub>1</sub> to examine the effectiveness of LAMAs on lung function. The trial reported the change from baseline in mean (SD) FEV<sub>1</sub> L to the end of the 28‐day trial period (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>). Two trials measured QoL using CFQ‐R domain scores (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> <p>All three trials measured and reported on adverse events including drug‐related adverse effects but for differing lengths of time (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Two trials reported on the number of exacerbations in the trial period; both trials recorded the number of participants experiencing one or more exacerbations (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> <p>None of the trials reported on the need for hospitalisation and/or antibiotics, or time to first exacerbation. </p> <p>Two trials reported other measures of lung function (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). For both of these trials, FEV<sub>1</sub> AUC<sub>0-4h</sub> (% predicted and L) was the primary endpoint and they also measured trough FEV<sub>1</sub>, FVC AUC<sub>0-4h</sub>, and trough FVC. </p> </section> </section> </section> <section id="CD012102-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded 16 trials (28 references) from the review because they did not meet the inclusion criteria. Brief descriptions of the excluded trials and reasons for exclusion are given in the tables (<a href="./references#CD012102-sec-0136" title="">Characteristics of excluded studies</a>). After a post hoc change to the protocol we excluded cross‐over trials due to the carry‐over effect of long‐acting medication leading to risk of bias. Three trials were excluded on this basis and have been described in an additional table (<a href="#CD012102-tbl-0003">Table 1</a>) (<a href="./references#CD012102-bbs2-0008" title="KeirGJ , SerisierDS , BowlerSD . Bronchodilator effects of tiotropium in stable cystic fibrosis - a placebo-controlled study. Respirology (Carlton, Vic.)2007;12 Suppl 1:A53. [ABSTRACT NO: TP097] [CENTRAL: 626263] [CFGD REGISTER: IB111] ">Keir 2007</a>; <a href="./references#CD012102-bbs2-0014" title="RodriguesJC , AddeFV , WickboldD , da VeigaCS , CardieriJ , LeoneC . Tiotropium acutely reduces the air trapping and improves airway conductance in pediatric cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:382. [ABSTRACT NO: 504] [CENTRAL: 921172] [CFGD REGISTER: IB101] ">Rodrigues 2008</a>; <a href="./references#CD012102-bbs2-0015" title="SalvatoreD , D'AndriaM . Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatric Pulmonology2002;34(1):11-5. [CENTRAL: 395585] [CFGD REGISTER: IB85] [PMID: 12112791]">Salvatore 2002</a>). </p> <div class="table" id="CD012102-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of excluded cross‐over trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Summary of results</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012102-bbs2-0006" title="HordvikNL , JudyCG , SammutPH , ColomboJL . The effects of low and high dose salmeterol on the lung function of hospitalized patients with cystic fibrosis. In: 11th Annual North American Cystic Fibrosis Conference. Vol. 347. 1997:301. [CFGD REGISTER: IB78a] HordvikNL , SammutPH , JudyCG , ColomboJL . Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatric Pulmonology1999;27(1):43-53. [CFGD REGISTER: IB78b] ">Hordvik 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration:</b> 3 days (salmeterol vs placebo given on one day of the 3 day trial. </p> <p><b>Design:</b> cross‐over RCT. </p> <p><b>Location:</b> single‐centre trial, USA. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number:</b> 18. </p> <p><b>Age</b>: mean (range) age 24 (14 – 36) years. </p> <p><b>Gender:</b> 38.9 % male. </p> <p><b>Disease status:</b> </p> <p>mean % predicted FEV<sub>1</sub> 56% (95% CI 22% to 91%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1:</b> salmeterol via MDI (42 mcg) single dose given on one day versus placebo. </p> <p><b>Comparator:</b> </p> <p>placebo via MDI, no details given.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub>:</b> mean % change in FEV<sub>1</sub> from baseline to 24 hours was 7.3% compared to 1.5% for placebo P &lt; 0.04. </p> <p>There was significant carry over to the next morning for salmeterol compared to placebo.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012102-bbs2-0008" title="KeirGJ , SerisierDS , BowlerSD . Bronchodilator effects of tiotropium in stable cystic fibrosis - a placebo-controlled study. Respirology (Carlton, Vic.)2007;12 Suppl 1:A53. [ABSTRACT NO: TP097] [CENTRAL: 626263] [CFGD REGISTER: IB111] ">Keir 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration:</b> 24 hours (1 day). </p> <p><b>Design:</b> cross‐over RCT. </p> <p><b>Location:</b> single‐centre, Australia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number:</b> 11. </p> <p><b>Age:</b> mean (SD) age 26.5 (5.4) years. </p> <p><b>Gender:</b> 45.5 % males. </p> <p><b>Disease status:</b> mean (SD) FEV<sub>1</sub> % predicted 45.4 (8.98). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1:</b> tiotropium (no details of dose). </p> <p><b>Comparator:</b> </p> <p>placebo (no details given).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: Keir was unable to show an effect from a single dose of tiotropium after 24 hours and there was no significant difference between tiotropium and placebo at any of the time points measured. </p> <p>No other outcomes reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012102-bbs2-0014" title="RodriguesJC , AddeFV , WickboldD , da VeigaCS , CardieriJ , LeoneC . Tiotropium acutely reduces the air trapping and improves airway conductance in pediatric cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:382. [ABSTRACT NO: 504] [CENTRAL: 921172] [CFGD REGISTER: IB101] ">Rodrigues 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration:</b> 24 hours. </p> <p><b>Design:</b> cross‐over RCT. </p> <p><b>Location:</b> not stated. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number:</b> 20. </p> <p><b>Age:</b> range 6 to 20 years. </p> <p><b>Gender:</b> not stated. </p> <p><b>Disease status:</b> </p> <p>FEV<sub>1</sub> &gt; 40% predicted. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1:</b> single dose of inhaled tiotropium (18.0 µg). </p> <p><b>Comparator:</b> </p> <p>single dose of placebo (empty capsule).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub>:</b> no significant change in FEV<sub>1</sub> after treatment with a single dose of tiotropium compared with placebo. </p> <p><b>Other lung function measures:</b> significant increase in airway conductance and a significant decrease in bronchial resistance after a single dose of tiotropium P &lt; 0.0001. </p> <p><b>FVC</b>: no significant change in FVC after the inhalation of tiotropium or placebo. </p> <p>No other outcomes reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012102-bbs2-0015" title="SalvatoreD , D'AndriaM . Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatric Pulmonology2002;34(1):11-5. [CENTRAL: 395585] [CFGD REGISTER: IB85] [PMID: 12112791]">Salvatore 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration:</b> 4 days. </p> <p><b>Design:</b> cross‐over RCT. </p> <p><b>Location:</b> single‐centre trial, Italy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number:</b> 23. </p> <p><b>Age:</b> range 18.5 to 36.6 years. </p> <p><b>Gender</b>: 56.5 % male. </p> <p><b>Disease status:</b> mean (SD) FVC % predicted 63.2 (10)%, mean (SD) FEV<sub>1</sub> % predicted 49.8 (12.9)%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1:</b> 4 puffs of salmeterol xinofoate 84.0 µg via MDI. </p> <p><b>Comparator:</b> </p> <p>placebo via MDI (no details given).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub>:</b> Salvatore reported significant improvements in FEV<sub>1</sub> % predicted (increase of 10.6% P &lt; 0.0001) the morning after treatment with salmeterol in the group of participants who responded to albuterol on the first day of the four‐day trial. Those participants who did not respond to albuterol showed no significant improvement in FEV<sub>1</sub> % predicted after treatment with salmeterol. </p> <p><b>Other lung function measures:</b> FEF<sub>25-75</sub> There was a significant improvement of 25.4%, P &lt; 0.0001 in mean FEF<sub>25-75</sub> the morning after treatment with salmeterol was seen in responders to an albuterol challenge. </p> <p>No other outcomes reported.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CF: cystic fibrosis<br/>FEF<sub>25-75</sub>: mid‐peak expiratory flow<br/>FEV<sub>1</sub>: forced expiratory volume in one second<br/>FVC: forced expiratory volume<br/>MDI: metered dose inhaler<br/>RCT: randomised controlled trial<br/>SD: standard deviation </p> </div> </div> <p>Nine trials did not report on the effects of a long‐acting bronchodilator (<a href="./references#CD012102-bbs2-0005" title="DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of cystic fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD012102-bbs2-0009" title="KonstanM , HilliardKA , KokerP , HamiltonAL , StaabA . Pharmacokinetics of BIIL 284 BS (amelubant), an oral once-daily LTB4 receptor antagonist, in adult and pediatric CF patients. Pediatric Pulmonology2003;Suppl 25:258-9. [CENTRAL: 451916] [CFGD REGISTER: IB41a] KonstanM , HilliardKA , KokerP , HamiltonAL . Safety and tolerability of BIIL 284 BS (amelubant), an oral once-daily LTB4 receptor antagonist, in adult and pediatric CF patients. Pediatric Pulmonology2003;Suppl 25:259. [CENTRAL: 451915] [CFGD REGISTER: IB41b] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. [CFGD REGISTER: IB41e] [PMID: 24440167]KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. Online Supplementary Material. [CENTRAL: 998111] [CFGD REGISTER: IB41h] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. Online Supplementary Material. [CENTRAL: 998113] [CFGD REGISTER: IB41j] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. Online Supplementary Material.. [CENTRAL: 998112] [CFGD REGISTER: IB41i] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. Online Supplementary Table 2. [CENTRAL: 998110] [CFGD REGISTER: IB41g] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. O Supplementary Table 1. [CENTRAL: 998109] [CFGD REGISTER: IB41f] KonstanMW , DoringG , LandsLC , HilliardKA , KokerP , BhattacharyaS , et al. Results of a phase 2 clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatric Pulmonology2005;40(Suppl 28):125. [CENTRAL: 593021] [CFGD REGISTER: IB41c] LympJ , HilliardK , RosenfeldM , KokerP , HamiltonA , KonstanM . Pulmonary exacerbations in a phase II clinical trial of BIIL 284 BS in CF: development and implementations of a respiratory and systemic symptoms questionnaire (RSSQ). Pediatric Pulmonology2009;44 Suppl 32:288. [ABSTRACT NO: 221] [CFGD REGISTER: IB41d] ">Konstan 2014</a>; <a href="./references#CD012102-bbs2-0011" title="NikolaizikWH , Jenni-GalovicV , SchoniMH . Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. European Journal of Pediatrics1996;155(7):608-11. [CFGD REGISTER: PI144] ">Nikolaizik 1996a</a>; <a href="./references#CD012102-bbs2-0012" title="OrlikT , SandsD , KlubaL . The influence of bronchodilators on chest physiotherapy effect in children with CF. Journal of cystic fibrosis2002;1(Suppl 1):S180. [CFGD REGISTER: IB183a] ">Orlik 2002</a><a href="./references#CD012102-bbs2-0013" title="RegelmannWE , ElliottGR , Clawson CC/WarwickWJ . Reduction of sputum Ps. Aeruginosa density by antibiotics improves lung function in CF more than bronchodilators and chest physiotherapy alone. Pediatric Pulmonology1988;Suppl 2:121. [ABSTRACT NO: 97] [CENTRAL: 291535] [CFGD REGISTER: PI65a] RegelmannWE , ElliottGR , WarwickWJ , ClawsonCC . Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. American Review of Respiratory Disease1990;141(4 Pt 1):914-21. [CENTRAL: 612638] [CFGD REGISTER: PI65b] [PMID: 2109558]">Regelmann 1990</a>; <a href="./references#CD012102-bbs2-0016" title="SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] ">Serisier 2007</a>; <a href="./references#CD012102-bbs2-0018" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. ">Weintraub 1989</a>; <a href="./references#CD012102-bbs2-0019" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The influence of ipratropium bromide on pulmonary function in patients with cystic fibrosis [Der Einfluss von Ipratropiumbromid auf die Lungenfunktion bei Patienten mit zystischer Fibrose]. Pneumologie, Sonderheft1990;44(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD012102-bbs2-0020" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmllerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. ">Ziebach 2001</a>). Konstan studied the effect of BIIL 284 BS, a LTB4 receptor antagonist which was taken orally rather than inhaled (<a href="./references#CD012102-bbs2-0009" title="KonstanM , HilliardKA , KokerP , HamiltonAL , StaabA . Pharmacokinetics of BIIL 284 BS (amelubant), an oral once-daily LTB4 receptor antagonist, in adult and pediatric CF patients. Pediatric Pulmonology2003;Suppl 25:258-9. [CENTRAL: 451916] [CFGD REGISTER: IB41a] KonstanM , HilliardKA , KokerP , HamiltonAL . Safety and tolerability of BIIL 284 BS (amelubant), an oral once-daily LTB4 receptor antagonist, in adult and pediatric CF patients. Pediatric Pulmonology2003;Suppl 25:259. [CENTRAL: 451915] [CFGD REGISTER: IB41b] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. [CFGD REGISTER: IB41e] [PMID: 24440167]KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. Online Supplementary Material. [CENTRAL: 998111] [CFGD REGISTER: IB41h] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. Online Supplementary Material. [CENTRAL: 998113] [CFGD REGISTER: IB41j] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. Online Supplementary Material.. [CENTRAL: 998112] [CFGD REGISTER: IB41i] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. Online Supplementary Table 2. [CENTRAL: 998110] [CFGD REGISTER: IB41g] KonstanMW , DoringG , HeltsheSL , LandsLC , HilliardKA , KokerP , et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. Journal of Cystic Fibrosis2014;13(2):148-55. O Supplementary Table 1. [CENTRAL: 998109] [CFGD REGISTER: IB41f] KonstanMW , DoringG , LandsLC , HilliardKA , KokerP , BhattacharyaS , et al. Results of a phase 2 clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatric Pulmonology2005;40(Suppl 28):125. [CENTRAL: 593021] [CFGD REGISTER: IB41c] LympJ , HilliardK , RosenfeldM , KokerP , HamiltonA , KonstanM . Pulmonary exacerbations in a phase II clinical trial of BIIL 284 BS in CF: development and implementations of a respiratory and systemic symptoms questionnaire (RSSQ). Pediatric Pulmonology2009;44 Suppl 32:288. [ABSTRACT NO: 221] [CFGD REGISTER: IB41d] ">Konstan 2014</a>). Two trials reported on the effects of inhaled antibiotics, one trial looked at nebulised tobramycin (<a href="./references#CD012102-bbs2-0011" title="NikolaizikWH , Jenni-GalovicV , SchoniMH . Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. European Journal of Pediatrics1996;155(7):608-11. [CFGD REGISTER: PI144] ">Nikolaizik 1996a</a>) and the other at parenteral antibiotics compared to placebo (<a href="./references#CD012102-bbs2-0013" title="RegelmannWE , ElliottGR , Clawson CC/WarwickWJ . Reduction of sputum Ps. Aeruginosa density by antibiotics improves lung function in CF more than bronchodilators and chest physiotherapy alone. Pediatric Pulmonology1988;Suppl 2:121. [ABSTRACT NO: 97] [CENTRAL: 291535] [CFGD REGISTER: PI65a] RegelmannWE , ElliottGR , WarwickWJ , ClawsonCC . Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. American Review of Respiratory Disease1990;141(4 Pt 1):914-21. [CENTRAL: 612638] [CFGD REGISTER: PI65b] [PMID: 2109558]">Regelmann 1990</a>). Three trials examined the effects of short‐acting beta‐2 agonists. Dodd and Orlik looked at salbutamol (<a href="./references#CD012102-bbs2-0005" title="DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of cystic fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD012102-bbs2-0012" title="OrlikT , SandsD , KlubaL . The influence of bronchodilators on chest physiotherapy effect in children with CF. Journal of cystic fibrosis2002;1(Suppl 1):S180. [CFGD REGISTER: IB183a] ">Orlik 2002</a>) whilst Serisier looked at the effects of albuterol (<a href="./references#CD012102-bbs2-0016" title="SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] ">Serisier 2007</a>). Three trials examined the effects of the short‐acting muscarinic antagonist bronchodilator ipratropium bromide (<a href="./references#CD012102-bbs2-0018" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. ">Weintraub 1989</a>; <a href="./references#CD012102-bbs2-0019" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The influence of ipratropium bromide on pulmonary function in patients with cystic fibrosis [Der Einfluss von Ipratropiumbromid auf die Lungenfunktion bei Patienten mit zystischer Fibrose]. Pneumologie, Sonderheft1990;44(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD012102-bbs2-0020" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmllerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. ">Ziebach 2001</a>); with the latter also looking at salbutamol and a combination of ipratropium and salbutamol. </p> <p>Two trials looked at the effects of a long‐acting bronchodilator, but the comparator was a short‐acting bronchodilator rather than placebo, no treatment or another long‐acting bronchodilator (<a href="./references#CD012102-bbs2-0007" title="HordvikNL , SammutPH , JudyCG , ColomboJL . A four week trial of high dose salmeterol vs. nebulized albuterol in patients with cystic fibrosis (CF). In: Fourteenth Annual North American Cystic Fibrosis Conference. Baltimore, Maryland, 2000:300. Hordvik NL , Sammut PH , Judy CG , Colombo JL . Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatric Pulmonology2002;34(4):287-96. ">Hordvik 2002</a>; <a href="./references#CD012102-bbs2-0017" title="TurchettaA , LucidiV , BellaS , RosatiP , PastoreE , GiordanoU , et al. Is salmeterol effective in children with cystic fibrosis. Israel Journal of Medical Sciences1996;32 Suppl:S191. [CFGD REGISTER: IB71] ">Turchetta 1996</a>). An earlier Hordvik trial looked at the effect of a long‐acting beta‐2 agonist in a three‐arm cross‐over trial. There was no washout period in between the cross‐over of treatments and we have since excluded cross‐over trials (<a href="./references#CD012102-bbs2-0006" title="HordvikNL , JudyCG , SammutPH , ColomboJL . The effects of low and high dose salmeterol on the lung function of hospitalized patients with cystic fibrosis. In: 11th Annual North American Cystic Fibrosis Conference. Vol. 347. 1997:301. [CFGD REGISTER: IB78a] HordvikNL , SammutPH , JudyCG , ColomboJL . Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatric Pulmonology1999;27(1):43-53. [CFGD REGISTER: IB78b] ">Hordvik 1999</a>). </p> <p>The remaining paper identified was a review rather than a trial and was excluded on this basis (<a href="./references#CD012102-bbs2-0010" title="NielsenKG . Lung function and bronchial responsiveness in young children. Clinical and research application. Danish Medical Bulletin2006;53(1):46-75. ">Nielsen 2006</a>). </p> </section> </section> <section id="CD012102-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias was assessed by both authors for all trials included in the review and the details are given in the table (<a href="./references#CD012102-sec-0135" title="">Characteristics of included studies</a>) and summarised below (<a href="#CD012102-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012102-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012102-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012102-sec-0062"> <h4 class="title">Allocation</h4> <section id="CD012102-sec-0063"> <h5 class="title">Sequence generation</h5> <p>All four of the included trials were described as randomised with three of them giving full details of the randomisation process and being deemed to be at low risk of bias (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Bradley and Ratjen randomised participants using a computer‐generated randomisation schedule and in the Konstan trial participants were randomised via a third‐party telephone interactive voice randomisation system. The remaining trial did not describe the randomisation process and was deemed to have an unclear risk of bias (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> </section> <section id="CD012102-sec-0064"> <h5 class="title">Allocation concealment</h5> <p>Allocation of participants was concealed in the Bradley trial where medication was prepared and coded by Boehringer Ingelheim in a blinded fashion (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>). Allocation was also adequately concealed in the Konstan trial, where allocation was made by a third‐party telephone randomisation system (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>), and in the Ratjen trial, where participants were allocated in a 1:2 placebo:active ratio in a blinded fashion (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). It was unclear whether allocation was concealed for the Turchetta trial as it was not described in the trial documentation (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> </section> </section> <section id="CD012102-sec-0065"> <h4 class="title">Blinding</h4> <p>Two trials were deemed to be at low risk of bias from blinding as they were stated to be double‐blind and the methods of blinding were well‐described (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). In the Bradley trial, Boehringer Ingelheim prepared and coded the medication in a blinded fashion and provided all trial supplies (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>). Similarly, in the Ratjen trial all the trial medication was prepared and coded in a blinded fashion (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). One trial was described as double‐blind but provided no further details of which parties were blinded or methods, so the risk of bias was deemed as unclear (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>). The Turchetta trial did not describe blinding but stated that the comparator was no treatment. It is therefore likely that the participants were aware of the group they had been assigned to and the trial was deemed to be at high risk of bias (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> </section> <section id="CD012102-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>One trial did not describe withdrawals and was judged to have an unclear risk of attrition bias (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). The remaining three trials all reported withdrawals, but numbers of withdrawals were low and reasons were given so they were judged as being at low risk of bias (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> </section> <section id="CD012102-sec-0067"> <h4 class="title">Selective reporting</h4> <p>Three of the four included trials were deemed to be at low risk of selective reporting bias and although the protocol was only available for one trial (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>), supplementary documentation was available online for the other two trials (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Furthermore, clinical trial registration documentation was available for three trials (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). For the trial where there was no protocol or supporting information, the outcomes reported were checked against those stated in the methods; one of the three primary outcomes listed in the methods (FVC) was not reported in the results and so this trial was considered to be at unclear risk of selective reporting bias (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> </section> <section id="CD012102-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>None of the trials were given a low‐risk rating for other potential sources of bias. Three of the trials were judged to have an unclear risk of bias based on the fact that they were funded by the pharmaceutical company Boehringer Ingelheim (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). In two trials Boehringer Ingelheim were involved in trial design, data collection and analysis, interpretation of data, preparation of the manuscript and decision to publish (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>); in the third trial they employed some of the authors (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>). </p> <p>One trial was only published in abstract from and there was therefore insufficient information to be able to identify other potential sources of bias (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> </section> </section> <section id="CD012102-sec-0069"> <h3 class="title" id="CD012102-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD012102-tbl-0001"><b>Summary of findings 1</b> Beta‐2 agonists versus placebo</a>; <a href="./full#CD012102-tbl-0002"><b>Summary of findings 2</b> LAMAs versus placebo</a> </p> <section id="CD012102-sec-0070"> <h4 class="title">Beta‐2 agonists versus placebo or usual treatment or another beta‐2 agonist</h4> <p>Only one trial (n = 16) is included in this comparison (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). A summary of the main findings is provided in the summary of findings table (<a href="./full#CD012102-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD012102-sec-0071"> <h5 class="title">Primary outcomes</h5> <section id="CD012102-sec-0072"> <h6 class="title">1. Change in FEV<sub>1</sub> from baseline (L and % predicted) </h6> <section id="CD012102-sec-0073"> <p><b>a. medium term (7 to 28 days)</b></p> <p>Turchetta reported that children who received salmeterol twice a day via a spacer showed an increase in FEV<sub>1</sub> (unit of measurement not specified) (P &lt; 0.05) compared to children who received no treatment; but no data were presented (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> <p>GRADE: the quality of this evidence was deemed to be very low.</p> </section> </section> <section id="CD012102-sec-0074"> <h6 class="title">2. Participant‐reported outcomes (including QoL and symptom scores)</h6> <p>The included trial did not present any participant‐reported outcomes.</p> </section> <section id="CD012102-sec-0075"> <h6 class="title">3. Adverse effects</h6> <p>The included trial did not report on adverse events.</p> </section> </section> <section id="CD012102-sec-0076"> <h5 class="title">Secondary outcomes</h5> <section id="CD012102-sec-0077"> <h6 class="title">1. Number of exacerbations of respiratory symptoms</h6> <p>The included trial did not report on this outcome.</p> </section> <section id="CD012102-sec-0078"> <h6 class="title">2. Need for hospitalisation or antibiotics or both</h6> <p>The included trial did not report on this outcome.</p> </section> <section id="CD012102-sec-0079"> <h6 class="title">3. Time to first exacerbation</h6> <p>The included trial did not report on this outcome.</p> </section> <section id="CD012102-sec-0080"> <h6 class="title">4. Other measures of lung function</h6> <section id="CD012102-sec-0081"> <p><b>a. PEFR (L per minute and % predicted)</b></p> <p>The included trial did not report on this outcome.</p> </section> <section id="CD012102-sec-0082"> <p><b>b. measures of bronchial hyper‐responsiveness and bronchodilator responsiveness</b></p> <p>The included trial did not report on this outcome.</p> </section> <section id="CD012102-sec-0083"> <p><b>c. FEF <sub>25-75</sub> (L per second and % predicted)</b></p> <p>i. medium term (7 to 28 days)</p> <p>The trial did not report FEF<sub>25-75</sub> in the medium term. </p> </section> <section id="CD012102-sec-0084"> <p><b>d. FVC (L and % predicted)</b></p> <p>Although the trial authors stated that FVC was measured, no results were reported.</p> </section> <section id="CD012102-sec-0085"> <p><b>e. any other measurements of lung function that are relevant</b></p> <p>No other measures of lung function were reported for this comparison.</p> </section> </section> </section> </section> <section id="CD012102-sec-0086"> <h4 class="title">Muscarinic antagonists versus placebo or usual treatment or another muscarinic antagonist</h4> <p>Three trials (n = 1066) were included in this comparison (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). A summary of the main findings is provided in the table (<a href="./full#CD012102-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD012102-sec-0087"> <h5 class="title">Primary outcomes</h5> <section id="CD012102-sec-0088"> <h6 class="title">1. Change in FEV<sub>1</sub> from baseline (L and % predicted) </h6> <p>Only one of the three trials reported a change in FEV<sub>1</sub> (L) from baseline after treatment with tiotropium (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>). </p> <section id="CD012102-sec-0089"> <p><b>a. medium term (7 to 28 days)</b></p> <p>This multiple‐dose trial compared two doses of tiotropium and placebo in two age groups, a younger age group (5 years up to 11 years) and an older age group (12 years and over) and reported data after 28 days of treatment for FEV<sub>1</sub> (L). Analysis of results from participants receiving 2.5 ųg of tiotropium or placebo showed no significant difference between the groups in the younger or older age group, MD ‐0.02 (95% CI ‐0.13 to 0.09) (<a href="./references#CD012102-fig-0007" title="">Analysis 1.1</a>) (<a href="#CD012102-fig-0003">Figure 3</a>). Likewise, there was no significant difference between groups allocated to 5 ųg of tiotropium or placebo, MD 0.00 (95% CI ‐0.10 to 0.10) (<a href="./references#CD012102-fig-0008" title="">Analysis 1.2</a>) (<a href="#CD012102-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD012102-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.1 Change from baseline in FEV1 (L) after 28 days of tiotropium 2.5ųg." data-id="CD012102-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.1 Change from baseline in FEV<sub>1</sub> (L) after 28 days of tiotropium 2.5ųg. </p> </div> </div> </div> <div class="figure" id="CD012102-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.2 Change from baseline in FEV1 (L) after 28 days of Tiotropium 5ųg." data-id="CD012102-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.2 Change from baseline in FEV<sub>1</sub> (L) after 28 days of Tiotropium 5ųg. </p> </div> </div> </div> <p>GRADE: we found the quality of this evidence to be low.</p> </section> </section> <section id="CD012102-sec-0090"> <h6 class="title">2. Participant‐reported outcomes (including QoL and symptom scores)</h6> <p>Two trials reported the change from baseline in CFQ‐R domain scores, but no data were presented (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). The authors state that there were no differences in CFQ‐R domain scores after 12 weeks of treatment with tiotropium. </p> <p>GRADE: low‐quality evidence.</p> </section> <section id="CD012102-sec-0091"> <h6 class="title">3. Adverse effects</h6> <section id="CD012102-sec-0092"> <p><b>a. frequency of adverse effects</b></p> <p>Three trials provided data on the frequency of adverse events and more specifically drug‐related adverse effects (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). The Konstan trial measured adverse effects over 28 days, whilst the remaining two trials reported adverse effects over 12 weeks (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> <p>i. medium term (7 to 28 days)</p> <p>For all adverse events, Konstan found little difference between the tiotropium group and the placebo group at either the 2.5 µg dose level, RR 1.01 (95% CI 0.61 to 1.68) or at the 5.0 µg dose level, RR 0.97 (95% CI 0.59 to 1.60) (<a href="./references#CD012102-fig-0009" title="">Analysis 1.3</a>). Similarly for severe adverse events, little difference was found between tiotropium and placebo after 2.5 ųg, RR 0.70 (95% CI 0.05 to 10.27) or 5 ųg, RR 0.58 (95% CI 0.04 to 8.61) (<a href="./references#CD012102-fig-0011" title="">Analysis 1.5</a>). For trial‐drug‐related adverse events, the results showed a higher frequency of events in the tiotropium group, but the CIs are wide and the result was not significant; 2.5 ųg, RR 2.14 (95% CI 0.09 to 49.08) and 5.0 ųg, RR 1.75 (95% CI 0.20 to 15.25) (<a href="./references#CD012102-fig-0013" title="">Analysis 1.7</a>). </p> <p>ii. longer term (28 days to three months)</p> <p>Two trials reported adverse events over a three‐month period (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Bradley reported the frequency of adverse events after 2.5 µg and 5 ųg tiotropium to be similar across all treatment groups, RR 1.01 (95% CI 0.92 to 1.11), RR 0.98 (95% CI 0.90 to 1.06), respectively (<a href="./references#CD012102-fig-0010" title="">Analysis 1.4</a>) (<a href="#CD012102-fig-0005">Figure 5</a>). The most commonly reported adverse events were cough, exacerbation of CF, pyrexia, nasopharyngitis and headache (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>). </p> <div class="figure" id="CD012102-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.4 Any adverse event after 12 weeks of treatment." data-id="CD012102-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.4 Any adverse event after 12 weeks of treatment. </p> </div> </div> </div> <p>The Ratjen trial only reported adverse events after inhalation of 5.0 µg tiotropium compared to placebo and found the frequency of adverse events to be similar between treatment and placebo groups (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). When combined, the results of the Bradley trial and the Ratjen trial were not significantly different from placebo, RR 0.98 (95% CI 0.90 to 1.06) (<a href="./references#CD012102-fig-0010" title="">Analysis 1.4</a>) (<a href="#CD012102-fig-0005">Figure 5</a>). The most commonly reported adverse event was cough (tiotropium 18% versus placebo 13%). </p> </section> <section id="CD012102-sec-0093"> <p><b>b. severity of adverse effects (where it has been reported)</b></p> <p>i. medium term (7 to 28 days)</p> <p>Konstan reported on severe adverse events and drug‐related adverse events at both dose levels (<a href="./references#CD012102-fig-0011" title="">Analysis 1.5</a>; <a href="./references#CD012102-fig-0013" title="">Analysis 1.7</a>). When comparing tiotropium 2.5 µg to placebo, two participants (one from each group) experienced serious adverse events (both of which were exacerbation in CF); neither event was considered to be related to the trial drug and no symptoms associated with LAMAs were reported (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>). </p> <p>When trial‐drug‐related events were examined separately, the tiotropium group were more likely to experience adverse events than the placebo group at both doses; 2.5 µg, RR 2.14 (95% CI 0.09 to 49.08) and 5.0 µg, RR 1.75 (95% CI 0.20 to 15.25) but these results were not significant (<a href="./references#CD012102-fig-0013" title="">Analysis 1.7</a>). </p> <p>ii. longer term (28 days to three months)</p> <p>Both the Bradley and Ratjen trials reported on adverse events categorised into serious adverse events and trial‐drug‐related adverse events after 12 weeks of treatment (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). There were no significant differences in either serious adverse events between the tiotropium 2.5 µg group or 5.0 µg compared to placebo, although there was a slightly higher risk in the tiotropium group; 2.5 µg, RR 1.88 (95% CI 0.77 to 4.59) and 5.0 µg, RR 1.43 (95% CI 0.72 to 2.84) (<a href="./references#CD012102-fig-0012" title="">Analysis 1.6</a>). </p> <p>GRADE: we deemed the quality of the evidence relating to adverse events to be high.</p> </section> </section> </section> <section id="CD012102-sec-0094"> <h5 class="title">Secondary outcomes</h5> <section id="CD012102-sec-0095"> <h6 class="title">1. Number of exacerbations of respiratory symptoms</h6> <p>Only one trial reported on the number of participants who experienced one or more exacerbations after 2.5 µg of tiotropium compared to placebo (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>) and two trials reported this outcome after 5.0 µg of tiotropium (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). There were fewer exacerbations both after tiotropium 2.5 µg, RR 0.82 (95% CI 0.41 to 1.65) and after 5.0 µg, RR 0.60 (95% CI 0.32 to 1.12), although neither result was significant (<a href="./references#CD012102-fig-0015" title="">Analysis 1.9</a>). </p> <p>GRADE: we deemed the quality of this evidence to be moderate.</p> </section> <section id="CD012102-sec-0096"> <h6 class="title">2. Need for hospitalisation or antibiotics or both</h6> <p>None of the trials reported on this outcome.</p> </section> <section id="CD012102-sec-0097"> <h6 class="title">3. Time to first exacerbation</h6> <p>None of the trials reported on this outcome.</p> </section> <section id="CD012102-sec-0098"> <h6 class="title">4. Other measures of lung function</h6> <section id="CD012102-sec-0099"> <p><b>a. PEFR (L per minute and % predicted)</b></p> <p>None of the trials reported on this outcome.</p> </section> <section id="CD012102-sec-0100"> <p><b>b. measures of bronchial hyper‐responsiveness and bronchodilator responsiveness</b></p> <p>None of the trials reported on this outcome.</p> </section> <section id="CD012102-sec-0101"> <p><b>c. FEF <sub>25-75</sub> (L per second and % predicted)</b></p> <p>One trial measured FEF<sub>25-75,</sub> but we were unable to enter the data into our analysis (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>). Bradley reported that both doses of tiotropium led to adjusted mean improvements in FEF<sub>25-75</sub>, but they were not significant (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>). Ratjen found no significant difference between tiotropium and placebo for this outcome (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> </section> <section id="CD012102-sec-0102"> <p><b>d. FVC (L and % predicted)</b></p> <p>None of the trials reported on this outcome.</p> </section> <section id="CD012102-sec-0103"> <p><b>e. any other measurements of lung function that are relevant</b></p> <p>i. FEV<sub>1</sub> AUC<sub>0-4h</sub> (% predicted and L) </p> <p>This outcome was a co‐primary efficacy endpoint in two trials (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Only Bradley reported data for the lower dose of tiotropium (2.5 µg) which resulted in a significant improvement in FEV<sub>1</sub> AUC<sub>0-4h</sub> after 12 weeks for both % predicted, MD 2.94% (95% CI 1.12 to 4.76) (<a href="./references#CD012102-fig-0016" title="">Analysis 1.10</a>) and L, MD 0.09 L (95% CI 0.03 to 0.15) (<a href="./references#CD012102-fig-0017" title="">Analysis 1.11</a>). Both Bradley and Ratjen reported on this outcome for the higher dose (5.0 µg) and when data were combined, improvements in FEV<sub>1</sub> AUC<sub>0-4h</sub> were significantly in favour of tiotropium both in terms of % predicted, MD 2.59 (95% CI 1.28 to 3.89) (<a href="./references#CD012102-fig-0016" title="">Analysis 1.10</a>) and L, MD 0.09 L (95% CI 0.05 to 0.13) (<a href="./references#CD012102-fig-0017" title="">Analysis 1.11</a>) (<a href="#CD012102-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD012102-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.11 Change from baseline in adjusted FEV1 AUC0-4h after 12 weeks (L)." data-id="CD012102-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.11 Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> after 12 weeks (L). </p> </div> </div> </div> <p>In both trials, a greater effect was seen in the 12 years and older age group at both dose levels than in the younger age group (<a href="./references#CD012102-fig-0018" title="">Analysis 1.12</a>; <a href="./references#CD012102-fig-0019" title="">Analysis 1.13</a>). At the lower dose level as reported only by Bradley, results for the younger group were not significant, MD 2.33% (95% CI ‐1.20 to 5.86), but they were for the older group, MD 3.12% (95% 1.03 to 5.21) (<a href="./references#CD012102-fig-0018" title="">Analysis 1.12</a>). At the higher dose level, combined data from Bradley and Ratjen again showed a non‐significant result for the younger participants, MD 1.97% (95% CI ‐0.57 to 4.52) and a statistically significant result for the older age group, MD 2.83% (95% CI 1.37 to 4.30) (<a href="./references#CD012102-fig-0019" title="">Analysis 1.13</a>). Neither trial reported the effect in L separately for each age group. </p> <p>GRADE: we found the quality of this evidence to be moderate.</p> <p>ii. Trough FEV<sub>1</sub> (% predicted and L) </p> <p>Results were similar for trough FEV<sub>1</sub>, with Bradley showing a significant improvement in trough FEV<sub>1</sub> % predicted for all participants at the lower dose, MD 2.25% (95% CI 0.28 to 4.22) and combined data from Bradley and Ratjen also showing a significant difference between tiotropium 5.0 µg and placebo, MD 1.81% (95% CI 0.44 to 3.18) (<a href="./references#CD012102-fig-0020" title="">Analysis 1.14</a>). When the data were reported separately for the younger and older age groups, there was no significant improvement in either age group at the lower dose of tiotropium (<a href="./references#CD012102-fig-0021" title="">Analysis 1.15</a>). At the higher dose, however, the combined data from both trials (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>) showed a significant improvement in trough FEV<sub>1</sub> (% predicted) in the older age group, MD 2.32 (95% CI 0.81 to 3.82) (<a href="./references#CD012102-fig-0022" title="">Analysis 1.16</a>). Results in L were only provided for all age groups combined. A significant improvement was shown in the tiotropium groups (both dose levels) compared to placebo; 2.5 µg, MD 0.06 L (95% CI 0.00 to 0.12) and 5.0 µg, MD 0.06 L (95% CI 0.03 to 0.10) (<a href="./references#CD012102-fig-0023" title="">Analysis 1.17</a>). </p> <p>GRADE: we found the quality of this evidence to be moderate.</p> <p>iii. FVC AUC<sub>0-4h</sub> (% predicted and L) </p> <p>This outcome was also reported by Bradley and Ratjen in the text of their trial reports, but no data were available for our analysis (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Bradley showed an improvement in FVC AUC<sub>0-4h</sub> (% predicted) after both doses of tiotropium, but only the higher dose reached significance (P = 0.002) (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>). Ratjen reported no significant difference between tiotropium and placebo (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> <p>iv. Trough FVC (% predicted and L)</p> <p>Again, the Bradley and Ratjen trials reported this outcome, but did not provide data for our analysis (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Bradley found improvements at both dose levels of tiotropium, but neither was statistically significant; 2.5 µg tiotropium (P = 0.4) and 5.0 µg tiotropium (P = 0.2) (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>). Ratjen also reported no difference between 5.0 µg tiotropium and placebo for trough FVC (% predicted) (P = 0.19) (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> <p>v. Residual volume (RV) and total lung capacity (TLC)</p> <p>None of the trials reported on this outcome.</p> </section> </section> </section> </section> <section id="CD012102-sec-0104"> <h4 class="title">Beta‐2 agonists versus muscarinic antagonists</h4> <p>None of the included trials compared beta‐2 agonists with muscarinic antagonists.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012102-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012102-sec-0105"></div> <section id="CD012102-sec-0106"> <h3 class="title" id="CD012102-sec-0106">Summary of main results</h3> <p>Our review aimed to look at the effect of long‐acting bronchodilators on clinical outcomes including participant‐reported outcomes and QoL.There have been very few trials looking at the effects of long‐acting beta‐2 agonist or muscarinic antagonist bronchodilators in people with CF and the trials that we found differed in design, duration of treatment and the outcomes measured. The trials included in this review only studied the effects of two drugs, one was the beta‐2 agonist salmeterol and the other was the muscarinic antagonist bronchodilator tiotropium. A summary of the main results is also given in the summary of findings table for each comparison (<a href="./full#CD012102-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012102-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD012102-sec-0107"> <h4 class="title">Beta‐2 agonists</h4> <p>The trial of salmeterol was published in 1998 and had a small number of participants (n = 16) (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). The authors reported a significant improvement in FEV<sub>1</sub> after treatment with salmeterol, but did not present data on participant‐reported outcomes, QoL or adverse events. In terms of secondary outcomes, the trial did not report on pulmonary exacerbations or hospitalisation, possibly due to the short duration of the treatment and follow‐up. The results were published only as an abstract and the quality of the evidence was very low. </p> </section> <section id="CD012102-sec-0108"> <h4 class="title">Muscarinic antagonists</h4> <p>The three trials that examined the effects of tiotropium at doses of 2.5 µg and 5.0 µg compared to placebo were much more recent and included larger numbers of participants (n = 1066) (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Two of the trials had the same design and outcomes and formed phase II and III of the same clinical investigation (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>); Konstan reported on the phase I trial related to these subsequent trials (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>). The mean change in FEV<sub>1</sub> from baseline was only reported in one of the three trials, but no effect of tiotropium was seen at any dose (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>). </p> <p>Two trials measured QoL using the CFQ‐R score and no difference was found between participants taking tiotropium and participants taking placebo after 12 weeks of treatment. There was also little difference between treatment and placebo groups for the frequency of adverse effects after either dose of tiotropium as measured by three of the trials (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Fewer participants reported one or more pulmonary exacerbations after 5.0 µg of tiotropium compared to placebo over 12 weeks, although this did not reach statistical significance (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> <p>The two linked trials measured FEV<sub>1</sub> AUC<sub>0-4h</sub> and trough FEV<sub>1</sub> as their primary outcomes (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). The phase II trial (n = 510) which was judged to have an overall low risk of bias, found a significant improvement in FEV<sub>1</sub> AUC<sub>0-4h</sub> after 12 weeks of tiotropium at both dose levels (2.5 µg and 5.0 µg) with a greater effect seen after the higher dose (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>). The phase III trial, also judged to have an overall low risk of bias, looked only at the 5.0 µg dose and found there to be small but non‐significant improvements in FEV<sub>1</sub> AUC<sub>0-4h</sub> after 12 weeks of tiotropium (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). When the two trials were entered into a meta‐analysis, the overall improvement in FEV<sub>1</sub> AUC<sub>0-4h</sub> was significant (<a href="./references#CD012102-fig-0016" title="">Analysis 1.10</a>). Trough FEV<sub>1</sub> showed similar results, with the phase II paper reporting a significant improvement after tiotropium compared to placebo and the phase III trial showing no significant improvement. Both trials reported a greater effect in the 12 years or older age group (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> </section> </section> <section id="CD012102-sec-0109"> <h3 class="title" id="CD012102-sec-0109">Overall completeness and applicability of evidence</h3> <p>The single trial of a long‐acting beta‐2 agonist has only been published in abstract form to date and we have found no further data despite attempts to contact the authors (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). The information is therefore limited and we were only able to present the results of the trial narratively. </p> <p>The evidence for beta‐2 agonists is older and only looks at the short‐ to medium‐term effects of the drug (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). Therefore we are unable to say how the treatment might improve lung function over the longer term. The trial also only recruited small numbers of participants and only children (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). The fact that the trial did not report on our second primary outcome of participant‐reported outcomes and QoL it makes it difficult for us to draw conclusions on how effective inhaled beta‐2 agonist bronchodilators would be in improving QoL for people with CF. </p> <p>The evidence for the muscarinic antagonist bronchodilator tiotropium was more robust and complete due to the larger numbers of participants and rigorous methodology employed in the trials of this drug. The three trials (full papers plus supplementary documentation) present results for both children and adults and report effects over a longer time period ranging from 28 days (<a href="./references#CD012102-bbs2-0002" title="KonstanMW , KokerPJ , SharmaA . Evaluation of the safety, tolerability and pharmacokinetics of tiotropium bromide in cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:367. [ABSTRACT NO: 463] [CENTRAL: 921171] [CFGD REGISTER: IB114b] KonstanMW , SharmaA , Moroni-ZentgrafP , WangF , KokerP . Safety, tolerability, and plasma exposure of tiotropium respimat® in children and adults with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery2015;28(2):137-44. [CENTRAL: 1070797] [CFGD REGISTER: IB114c] [EMBASE: 2015896887]NCT02172534. Safety, tolerability and pharmacokinetics of tiotropium in cystic fibrosis patients [A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the respimat® device in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/study/NCT02172534 Date first received: 20 June 2014. [CFGD REGISTER: IB114a] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Konstan 2015</a>) to 12 weeks (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). This allowed us to look at whether treatment gradually improves symptoms over a longer time. Adverse effects were reported in all three trials which provides a more complete picture of whether there is a place for long‐acting muscarinic antagonist bronchodilators for treating of children and adults with CF. There is a need to minimise adverse effects from treatments and the finding that there was little difference between long‐acting bronchodilators and placebo is important. </p> <p>However, two of the three trials of LAMAs did not report our primary outcome of change from baseline in FEV<sub>1</sub>. Whilst they did report FEV<sub>1</sub>, it was as FEV<sub>1</sub> area under the curve <sub>0-4h</sub>. The trial authors selected this as their primary outcome as they felt it gave a more accurate measure of change in lung function over time (<a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). </p> <p>We should also note that two of the trials allowed included participants to continue their regular medication, which in some cases included a short‐acting bronchodilator (<a href="./references#CD012102-bbs2-0001" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One2014;9(9):e106195. [CENTRAL: 1114022] [CFGD REGISTER: IB99d] [5500131000000316] [PMCID:: PMC4154718] [PMID: 25188297]ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO: 80] [CENTRAL: 921613] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis [A randomized, double-blind, placebo-controlled parallel group study to Investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the respimat device for 12 weeks in patients with cystic fibrosis.]. Clinicaltrials.gov/ct2/show/NCT00737100 Date first received: 15 August 2008. [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. ">Bradley 2014</a>; <a href="./references#CD012102-bbs2-0003" title="GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT01179347. Tiotropium bromide in cystic fibrosis [A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 mcg administered once daily via the respimat® device in patients with cystic fibrosis]. ClinicalTrials.gov/ct2/show/NCT01179347 Date first received: 10 August 2010. [CFGD REGISTER: IB100a] RatjenF , KokerP , GellerD , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomised placebo-controlled trial. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO: 61] [CENTRAL: 921647] [CFGD REGISTER: IB100b] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium Respimat® in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CENTRAL: 1051537] [CFGD REGISTER: IB100d // IB99e] [5500133000000013] [PMID: 25819269]SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>). Whilst the addition of a long‐acting bronchodilator may improve lung function, if it is taken in addition to short‐acting bronchodilators it will only add to the treatment burden rather than reduce it. </p> </section> <section id="CD012102-sec-0110"> <h3 class="title" id="CD012102-sec-0110">Quality of the evidence</h3> <section id="CD012102-sec-0111"> <h4 class="title">Beta‐2 agonists</h4> <p>The evidence presented has several limitations in terms of the number of trials and the quality of included trials. Only one trial was found which matched our inclusion criteria. The quality of the evidence from this trial is very limited as it is only reported in abstract form and we have been unable to find further references to the trial (<a href="./references#CD012102-bbs2-0004" title="TurchettaA , LucidiV , CalzolariA , SalernoT , RosatiP , CastroM . Effects of salmeterol on maximal oxygen consumption (VO2max) in children with cystic fibrosis (CF). European Respiratory Journal1998;12 Suppl 28:391s. [CFGD REGISTER: IB115] ">Turchetta 1998</a>). </p> <p>The trial reported on our primary outcome of change in FEV<sub>1</sub> from baseline but the quality of the evidence was downgraded twice due to risk of bias within the trial; once because of imprecision due to small numbers and once due to indirectness as the trial only included children (<a href="./full#CD012102-tbl-0001">summary of findings Table 1</a>). </p> <p>The trial did not report on our remaining primary or secondary outcomes.</p> </section> <section id="CD012102-sec-0112"> <h4 class="title">Muscarinic antagonists</h4> <p>Although there are only a limited number of trials (n = 3) looking at the effects of LAMAs the overall quality of the evidence is moderate (<a href="./full#CD012102-tbl-0002">summary of findings Table 2</a>). </p> <p>However, only one of the three included trials of tiotropium reported on our primary outcome of change in FEV<sub>1</sub> from baseline. The quality of the evidence provided by this trial was deemed to be low and was downgraded once for risk of bias (due to unclear blinding methods) and once due to imprecision from a small sample size with only the one trial contributing data. Two trials measured QoL but the evidence was downgraded twice because analysable data were not presented in the paper (only narrative) and there was risk of bias from a lack of information. It is therefore difficult to draw conclusions for this outcome. The lack of such data is likely to be due to the relatively short‐term nature of the trials which are not able to measure longer‐term outcomes, but it illustrates an important gap in the evidence. The quality of evidence for our remaining primary outcome, adverse events, was deemed to be high. Two trials contributed to the adverse events data, both including large numbers of participants and there was no reason to downgrade the evidence. </p> <p>In terms of the secondary outcome measures in our review, the quality of the evidence for participants reporting at least one pulmonary exacerbation during the trial period was deemed to be moderate. Similarly, for the other measures of lung function, the quality of evidence was moderate with the reason for downgrading being that this outcome is not routinely used in the clinical area. </p> </section> </section> <section id="CD012102-sec-0113"> <h3 class="title" id="CD012102-sec-0113">Potential biases in the review process</h3> <p>It is unlikely that we have missed any trials; in addition to carrying out a rigorous search, we scanned references of included trials and contacted pharmaceutical companies for any unpublished work. Both authors scanned titles and extracted data independently to reduce bias and to detect errors in data extraction or interpretation. </p> </section> <section id="CD012102-sec-0114"> <h3 class="title" id="CD012102-sec-0114">Agreements and disagreements with other studies or reviews</h3> <p>Since the previously published version of the review (<a href="./references#CD012102-bbs2-0044" title="HalfhideC , EvansHJ , CourielJ . Inhaled bronchodilators for cystic fibrosis. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD003428. [DOI: 10.1002/14651858.CD003428.pub2]">Halfhide 2005</a>), there has been limited additional evidence published with respect to the use of long‐acting bronchodilators. Simiarly there have been few other reviews on the subject. Kent reviewed the "complex web" of CF and asthma and came to similar conclusions to this review; in particular, they emphasized the lack of long‐term evidence (<a href="./references#CD012102-bbs2-0034" title="KentBD , LaneSJ , vanBeekEJ , DoddJD , CostelloRW , TiddensHA . Asthma and cystic fibrosis: a tangled web. Pediatric Pulmonology2014;49(3):205-13.">Kent 2014</a>). However, since this review was completed, a further publication in PLoS One has reported on the impact of long‐term tiotropium therapy on the annual decline in lung function (<a href="./references#CD012102-bbs2-0025" title="BrandtC , ThronickeA , Roehmel JF , KrannichA , StaabD , SchwarzC . Impact of long-term tiotropium Bbromide therapy on annual lung function decline in adult patients with cystic fibrosis. PLoS ONE2016;11(6):e0158193.">Brandt 2016</a>). This retrospective cohort study estimated an annual decline in lung function by utilizing longitudinal data for FEV<sub>1</sub>, and demonstrated a significantly slower decline in the mean annual change in FEV<sub>1</sub> in people using tiotropium. Since this was not a RCT, it would not have been included in this Cochrane Review, but it does reinforce the need to perform further long‐term studies of the use of long‐acting bronchodilators in people with CF. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012102-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012102-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012102-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.1 Change from baseline in FEV1 (L) after 28 days of tiotropium 2.5ųg." data-id="CD012102-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.1 Change from baseline in FEV<sub>1</sub> (L) after 28 days of tiotropium 2.5ųg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.2 Change from baseline in FEV1 (L) after 28 days of Tiotropium 5ųg." data-id="CD012102-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.2 Change from baseline in FEV<sub>1</sub> (L) after 28 days of Tiotropium 5ųg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.4 Any adverse event after 12 weeks of treatment." data-id="CD012102-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.4 Any adverse event after 12 weeks of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.11 Change from baseline in adjusted FEV1 AUC0-4h after 12 weeks (L)." data-id="CD012102-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Inhaled LAMAs versus placebo, outcome: 1.11 Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> after 12 weeks (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 1: Change from baseline in FEV1 (L) after 28 days of tiotropium 2.5ųg" data-id="CD012102-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 1: Change from baseline in FEV<sub>1</sub> (L) after 28 days of tiotropium 2.5ųg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 2: Change from baseline in FEV1 (L) after 28 days of Tiotropium 5ųg" data-id="CD012102-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 2: Change from baseline in FEV<sub>1</sub> (L) after 28 days of Tiotropium 5ųg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 3: Any adverse event after 28 days of treatment" data-id="CD012102-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 3: Any adverse event after 28 days of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 4: Any adverse event after 12 weeks of treatment" data-id="CD012102-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 4: Any adverse event after 12 weeks of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 5: Severe adverse events after 28 days of treatment" data-id="CD012102-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 5: Severe adverse events after 28 days of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 6: Severe adverse events after 12 weeks of treatment" data-id="CD012102-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 6: Severe adverse events after 12 weeks of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 7: Trial drug‐related adverse events after 28 days of treatment" data-id="CD012102-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 7: Trial drug‐related adverse events after 28 days of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 8: Trial drug‐related adverse events after 12 weeks of treatment" data-id="CD012102-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 8: Trial drug‐related adverse events after 12 weeks of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 9: Participants reporting ≥ 1 pulmonary exacerbation during 12 weeks of treatment" data-id="CD012102-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 9: Participants reporting ≥ 1 pulmonary exacerbation during 12 weeks of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 10: Change from baseline in adjusted FEV1 AUC0-4h after 12 weeks of treatment (% predicted)" data-id="CD012102-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 10: Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> after 12 weeks of treatment (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 11: Change from baseline in adjusted FEV1 AUC0-4h after 12 weeks (L)" data-id="CD012102-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 11: Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> after 12 weeks (L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 12: Change from baseline in adjusted FEV1 AUC0-4h (% predicted) after 12 weeks of tiotropium 2.5 µg by age group" data-id="CD012102-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 12: Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> (% predicted) after 12 weeks of tiotropium 2.5 µg by age group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 13: Change from baseline in adjusted FEV1 AUC0-4h (% predicted) after 12 weeks of tiotropium 5.0 µg by age group" data-id="CD012102-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 13: Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> (% predicted) after 12 weeks of tiotropium 5.0 µg by age group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 14: Change from baseline in adjusted trough FEV1 (% predicted) after 12 weeks" data-id="CD012102-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 14: Change from baseline in adjusted trough FEV<sub>1</sub> (% predicted) after 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 15: Change from baseline in adjusted trough FEV1 (% predicted) after 12 weeks of treatment with 2.5 µg tiotropium by age" data-id="CD012102-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 15: Change from baseline in adjusted trough FEV<sub>1</sub> (% predicted) after 12 weeks of treatment with 2.5 µg tiotropium by age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 16: Change from baseline in adjusted trough FEV1 (% predicted) after 12 weeks of treatment with tiotropium 5.0 µg" data-id="CD012102-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 16: Change from baseline in adjusted trough FEV<sub>1</sub> (% predicted) after 12 weeks of treatment with tiotropium 5.0 µg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012102-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/urn:x-wiley:14651858:media:CD012102:CD012102-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Inhaled LAMAs versus placebo, Outcome 17: Change from baseline in adjusted trough FEV1 after 12 weeks (L)" data-id="CD012102-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_t/tCD012102-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Inhaled LAMAs versus placebo, Outcome 17: Change from baseline in adjusted trough FEV<sub>1</sub> after 12 weeks (L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/media/CDSR/CD012102/image_n/nCD012102-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012102-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Beta‐2 agonists versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐2 agonists (salmeterol) compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> hospital inpatients </p> <p><b>Intervention:</b> long‐acting beta‐2 agonist (salmeterol) </p> <p><b>Comparison:</b> inhaled placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>salmeterol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub>: change from baseline </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Children who received salmeterol twice a day showed a significant increase in FEV<sub>1</sub> compared to children who received no treatment P &lt; 0.05. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This trial included only children. The unit of measurement was not specified and only a P value was presented. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant‐reported outcomes: quality of life (measured by CFQ‐R)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events after tiotropium 5.0 µg</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary exacerbations</p> <p>Follow‐up: N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other measures of lung function</p> <p>Follow‐up: N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Outcome not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEF<sub>25-75</sub> </b> : mid peak expiratory flow; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>FVC</b> : forced vital capacity; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded twice due to risk of bias ‐ this trial was at high risk of bias for blinding and at unclear risk of bias for four of the remaining five domains. The randomisation process and allocation concealment were unclear which was reflected in the risk of bias assessment. </p> <p>2. Downgraded once due to imprecision ‐ very small sample size from one trial.</p> <p>3. Downgraded once due to indirectness ‐ the trial only included children.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Beta‐2 agonists versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012102-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">LAMAs versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Inhaled tiotropium compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> inhaled tiotropium 2.5 µg to 5.0 µg </p> <p><b>Comparison:</b> inhaled placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Tiotropium</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub>: mean change from baseline (L) </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (L) in the placebo group ranged from ‐0.02 to zero. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (L) after tiotropium 2.5 µg was 0.02 L lower than placebo (0.13 lower to 0.09 higher). </p> <p>There was no mean change in FEV<sub>1</sub> (L) after tiotropium 5 µg (mean difference = zero (0.1 L lower to 0.1 L higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (2.5 µg dose)</p> <p>38 (5 µg dose)</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference was seen between tiotropium and placebo at either dose or in either age group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported outcomes: quality of life (measured by CFQ‐R)</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no differences in CFQ‐R domain scores after 12 weeks of treatment with tiotropium. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>974<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were given for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events after tiotropium 5.0 µg</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>755 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>725 per 1000</b><br/>(664 to 785) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (0.88 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further trial reported adverse events over 28 days and so we have not combined the results. There were no significant differences between tiotropium at 2.5 or 5 µg and placebo with regard to adverse events (P = 0.97, P = 0.91 respectively). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary exacerbations: participants reporting ≥1 pulmonary exacerbation during the trial period after tiotropium 5 µg </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(2 to 6 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> (0.32 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>805<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The overall effect was not statistically significant.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other measures of lung function: mean change from baseline in FEV<sub>1</sub> AUC<sub>0-4h</sub> (% predicted) after tiotropium 5.0 µg </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> ranged across placebo groups from<br/>‐1.74% predicted to 0.87% predicted. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change across both age groups in the tiotropium 5.0 µg groups was 2.59% higher (1.28 to 3.89) than placebo. </p> <p>The mean change across the 5 to ≤ 11 year age group was 1.97% higher (‐0.57 to 4.52) than placebo. </p> <p>The mean change across the ≥ 12 year age group was 2.83% higher (1.37, 4.30) than placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>770</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In both trials, a greater effect was seen in the ≥ 12 year age group than the younger age group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other measures of lung function: mean change from baseline in trough FEV<sub>1</sub> (% predicted) after tiotropium 5.0 µg </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> ranged across placebo groups from ‐1.44% predicted to 0.72% predicted. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change across both age groups in the tiotropium 5.0 µg groups was 1.81% higher (0.44 to 3.18) than placebo. </p> <p>The mean change across the 5 to ≤ 11 year age group was 0.88% higher (‐1.76 to 3.53) than placebo. </p> <p>The mean change across the ≥ 12 year age group was 2.325 higher (0.81, 3.82) than placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>772</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFQ‐R</b> : cystic fibrosis questionnaire (revised); <b>CI</b> : confidence interval; <b>FEF<sub>25-75</sub> </b> : mid peak expiratory flow; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>FVC</b> : forced vital capacity; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once due to risk of bias as methods of blinding were not described.</p> <p>2. Downgraded once due to imprecision due to a small sample size, low event rates and only one trial contributing data. </p> <p>3. Downgraded twice due to imprecision as the data weren't presented and unclear risk of bias from lack of information. </p> <p>4. Downgraded once due to imprecision due to low event rates.</p> <p>5. Downgraded once due to indirectness: this is not a measure used routinely in the clinical area. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">LAMAs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012102-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of excluded cross‐over trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Summary of results</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012102-bbs2-0006" title="HordvikNL , JudyCG , SammutPH , ColomboJL . The effects of low and high dose salmeterol on the lung function of hospitalized patients with cystic fibrosis. In: 11th Annual North American Cystic Fibrosis Conference. Vol. 347. 1997:301. [CFGD REGISTER: IB78a] HordvikNL , SammutPH , JudyCG , ColomboJL . Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatric Pulmonology1999;27(1):43-53. [CFGD REGISTER: IB78b] ">Hordvik 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration:</b> 3 days (salmeterol vs placebo given on one day of the 3 day trial. </p> <p><b>Design:</b> cross‐over RCT. </p> <p><b>Location:</b> single‐centre trial, USA. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number:</b> 18. </p> <p><b>Age</b>: mean (range) age 24 (14 – 36) years. </p> <p><b>Gender:</b> 38.9 % male. </p> <p><b>Disease status:</b> </p> <p>mean % predicted FEV<sub>1</sub> 56% (95% CI 22% to 91%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1:</b> salmeterol via MDI (42 mcg) single dose given on one day versus placebo. </p> <p><b>Comparator:</b> </p> <p>placebo via MDI, no details given.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub>:</b> mean % change in FEV<sub>1</sub> from baseline to 24 hours was 7.3% compared to 1.5% for placebo P &lt; 0.04. </p> <p>There was significant carry over to the next morning for salmeterol compared to placebo.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012102-bbs2-0008" title="KeirGJ , SerisierDS , BowlerSD . Bronchodilator effects of tiotropium in stable cystic fibrosis - a placebo-controlled study. Respirology (Carlton, Vic.)2007;12 Suppl 1:A53. [ABSTRACT NO: TP097] [CENTRAL: 626263] [CFGD REGISTER: IB111] ">Keir 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration:</b> 24 hours (1 day). </p> <p><b>Design:</b> cross‐over RCT. </p> <p><b>Location:</b> single‐centre, Australia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number:</b> 11. </p> <p><b>Age:</b> mean (SD) age 26.5 (5.4) years. </p> <p><b>Gender:</b> 45.5 % males. </p> <p><b>Disease status:</b> mean (SD) FEV<sub>1</sub> % predicted 45.4 (8.98). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1:</b> tiotropium (no details of dose). </p> <p><b>Comparator:</b> </p> <p>placebo (no details given).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: Keir was unable to show an effect from a single dose of tiotropium after 24 hours and there was no significant difference between tiotropium and placebo at any of the time points measured. </p> <p>No other outcomes reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012102-bbs2-0014" title="RodriguesJC , AddeFV , WickboldD , da VeigaCS , CardieriJ , LeoneC . Tiotropium acutely reduces the air trapping and improves airway conductance in pediatric cystic fibrosis patients. Pediatric Pulmonology2008;43 Suppl 31:382. [ABSTRACT NO: 504] [CENTRAL: 921172] [CFGD REGISTER: IB101] ">Rodrigues 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration:</b> 24 hours. </p> <p><b>Design:</b> cross‐over RCT. </p> <p><b>Location:</b> not stated. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number:</b> 20. </p> <p><b>Age:</b> range 6 to 20 years. </p> <p><b>Gender:</b> not stated. </p> <p><b>Disease status:</b> </p> <p>FEV<sub>1</sub> &gt; 40% predicted. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1:</b> single dose of inhaled tiotropium (18.0 µg). </p> <p><b>Comparator:</b> </p> <p>single dose of placebo (empty capsule).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub>:</b> no significant change in FEV<sub>1</sub> after treatment with a single dose of tiotropium compared with placebo. </p> <p><b>Other lung function measures:</b> significant increase in airway conductance and a significant decrease in bronchial resistance after a single dose of tiotropium P &lt; 0.0001. </p> <p><b>FVC</b>: no significant change in FVC after the inhalation of tiotropium or placebo. </p> <p>No other outcomes reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012102-bbs2-0015" title="SalvatoreD , D'AndriaM . Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatric Pulmonology2002;34(1):11-5. [CENTRAL: 395585] [CFGD REGISTER: IB85] [PMID: 12112791]">Salvatore 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration:</b> 4 days. </p> <p><b>Design:</b> cross‐over RCT. </p> <p><b>Location:</b> single‐centre trial, Italy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number:</b> 23. </p> <p><b>Age:</b> range 18.5 to 36.6 years. </p> <p><b>Gender</b>: 56.5 % male. </p> <p><b>Disease status:</b> mean (SD) FVC % predicted 63.2 (10)%, mean (SD) FEV<sub>1</sub> % predicted 49.8 (12.9)%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1:</b> 4 puffs of salmeterol xinofoate 84.0 µg via MDI. </p> <p><b>Comparator:</b> </p> <p>placebo via MDI (no details given).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub>:</b> Salvatore reported significant improvements in FEV<sub>1</sub> % predicted (increase of 10.6% P &lt; 0.0001) the morning after treatment with salmeterol in the group of participants who responded to albuterol on the first day of the four‐day trial. Those participants who did not respond to albuterol showed no significant improvement in FEV<sub>1</sub> % predicted after treatment with salmeterol. </p> <p><b>Other lung function measures:</b> FEF<sub>25-75</sub> There was a significant improvement of 25.4%, P &lt; 0.0001 in mean FEF<sub>25-75</sub> the morning after treatment with salmeterol was seen in responders to an albuterol challenge. </p> <p>No other outcomes reported.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CF: cystic fibrosis<br/>FEF<sub>25-75</sub>: mid‐peak expiratory flow<br/>FEV<sub>1</sub>: forced expiratory volume in one second<br/>FVC: forced expiratory volume<br/>MDI: metered dose inhaler<br/>RCT: randomised controlled trial<br/>SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of excluded cross‐over trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/full#CD012102-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012102-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Inhaled LAMAs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change from baseline in FEV<sub>1</sub> (L) after 28 days of tiotropium 2.5ųg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.13, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Participants aged 5 ‐ ≤ 11 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.20, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Participants aged ≥ 12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.15, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Change from baseline in FEV<sub>1</sub> (L) after 28 days of Tiotropium 5ųg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.10, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Participants aged 5 ‐ ≤ 11 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.16, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Participants aged ≥ 12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.14, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Any adverse event after 28 days of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Tiotropium 2.5 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.61, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Tiotropium 5.0 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.59, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Any adverse event after 12 weeks of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Tiotropium 2.5 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Tiotropium 5.0 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.90, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Severe adverse events after 28 days of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Tiotropium 2.5 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.05, 10.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Tiotropium 5.0 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.04, 8.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Severe adverse events after 12 weeks of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Tiotropium 2.5 ųg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.77, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Tiotropium 5.0 ųg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.72, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Trial drug‐related adverse events after 28 days of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Tiotropium 2.5 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.09, 49.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Tiotropium 5.0 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.20, 15.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Trial drug‐related adverse events after 12 weeks of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Tiotropium 2.5 ųg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.54, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Tiotropium 5.0 ųg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.77, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Participants reporting ≥ 1 pulmonary exacerbation during 12 weeks of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Tiotropium 2.5 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.41, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Tiotropium 5.0 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.32, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> after 12 weeks of treatment (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Tiotropium 2.5 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [1.12, 4.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Tiotropium 5.0 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [1.28, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> after 12 weeks (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Tiotropium 2.5 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.03, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Tiotropium 5.0 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.05, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> (% predicted) after 12 weeks of tiotropium 2.5 µg by age group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Age group 5 to ≤11 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [‐1.20, 5.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Age group ≥12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [1.03, 5.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Change from baseline in adjusted FEV<sub>1</sub> AUC<sub>0-4h</sub> (% predicted) after 12 weeks of tiotropium 5.0 µg by age group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Age group 5 to ≤11 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [‐0.57, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Age group ≥12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [1.37, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Change from baseline in adjusted trough FEV<sub>1</sub> (% predicted) after 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Tiotropium 2.5 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.28, 4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Tiotropium 5.0 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.44, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Change from baseline in adjusted trough FEV<sub>1</sub> (% predicted) after 12 weeks of treatment with 2.5 µg tiotropium by age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Age group 5 to ≤11 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.54 [‐0.24, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Age group ≥12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [‐0.47, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Change from baseline in adjusted trough FEV<sub>1</sub> (% predicted) after 12 weeks of treatment with tiotropium 5.0 µg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Age group 5 ‐ ≤11 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [‐1.76, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Age group ≥12 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.81, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Change from baseline in adjusted trough FEV<sub>1</sub> after 12 weeks (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Tiotropium 2.5 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Tiotropium 5.0 µg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.03, 0.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Inhaled LAMAs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012102.pub2/references#CD012102-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012102.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012102-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012102-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012102-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012102-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012102\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012102\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012102\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012102\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012102\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012102.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012102.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012102.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012102.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012102.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729489424"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012102.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729489429"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012102.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ede20bf6ebd65',t:'MTc0MDcyOTQ4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 